Document:

Exhibit 10.1

 

LOAN AND SECURITY AGREEMENT

 

THIS LOAN AND SECURITY
AGREEMENT is made and dated as of December 15, 2020 and is entered into by and between Soligenix, Inc., a corporation incorporated
in the State of Delaware, and each of its Subsidiaries from time to time party hereto, including the Subsidiaries set forth on
Schedule I hereto (collectively referred to as “Borrower”), Pontifax Medison Finance (Israel) L.P. and Pontifax Medison
Finance (Cayman) L.P. (each a “Lender” and collectively, the “Lenders”) and Pontifax Medison Finance GP,
L.P., in its capacity as administrative agent and collateral agent for itself and Lenders (in such capacity, “Agent”).

 

RECITALS

 

A. Borrower
has requested Lenders to make available to Borrower a loan or loans in an aggregate principal amount of up to Twenty Million Dollars
($20,000,000.00) (the “Term Loan”) to provide for working capital and general corporate purposes in the OCB; and

 

B. Lenders
are willing to make the Term Loan on the terms and conditions set forth in this Agreement.

 

AGREEMENT

 

NOW, THEREFORE, Borrower,
Agent and Lenders agree as follows:

 

SECTION 1. DEFINITIONS AND RULES
OF CONSTRUCTION

 

1.1. Unless
otherwise defined herein, the following capitalized terms shall have the following meanings:

 

“Affiliate”
means (a) any Person that directly or indirectly controls, is controlled by, or is under common control with the Person in
question or (b) any Person directly or indirectly owning, controlling or holding the power to vote twenty percent (20%) or
more of the outstanding voting securities of another Person, (c) any Person twenty percent (20%) or more of whose outstanding
voting securities are directly or indirectly owned, controlled or held by another Person with power to vote such securities. As
used in the definition of “Affiliate,” the term “control” means the possession, directly or indirectly,
of the power to direct or cause the direction of the management and policies of a Person, whether through ownership of voting securities,
by contract or otherwise. Notwithstanding the foregoing, neither Lender, Agent nor any of their Affiliates shall be deemed to be
an Affiliate of Borrower for purposes of this Agreement or any other Loan Document.

 

“Agent”
has the meaning given to such term in the preamble to this Agreement.

 

“Agreement”
means this Loan and Security Agreement, as amended from time to time.

 

“Amortization
Date” means the last Business Day prior to the lapse of 24 months following the Closing Date.

 

“Anti-Corruption
Laws” shall mean all laws, rules, and regulations of any jurisdiction applicable to Borrower or any of its Affiliates from
time to time concerning or relating to bribery or corruption, including without limitation the United States Foreign Corrupt Practices
Act of 1977, as amended, the UK Bribery Act 2010 and other similar legislation in any other jurisdictions.

 

“Anti-Terrorism Laws”
means any laws, rules, regulations or orders relating to terrorism or money laundering, including without limitation Executive
Order No. 13224 (effective September 24, 2001), the USA PATRIOT Act, the laws comprising or implementing the Bank Secrecy
Act, and the laws administered by OFAC.

 

“Assignee”
has the meaning given to such term in Section 11.13.

 

“Authorized
Shares” has the meaning given to such term in Section 5.18.

 

     

     

    

 

“Blocked Person”
means: (a) a Person listed in the annex to, or that is otherwise subject to the provisions of, Executive Order No. 13224,
(b) a Person owned or controlled by, or acting for or on behalf of, any Person that is listed in the annex to, or is otherwise
subject to the provisions of, Executive Order No. 13224, (c) a Person with which a Lender is prohibited from dealing or otherwise
engaging in any transaction by any Anti-Terrorism Law, (d) a Person that commits, threatens or conspires to commit or supports
“terrorism” as defined in Executive Order No. 13224, or (e) a Person that is named a “specially designated
national” or “blocked person” on the most current list published by OFAC or other similar list.

 

“Borrower”
has the meaning given to such term in the preamble to this Agreement.

 

“Business Day”
means any day other than Saturday, Sunday and any other day on which banking institutions in the State of New York are closed for
business.

 

“Cash”
means all cash and Cash Equivalents.

 

“Cash Equivalents”
means (a) marketable direct obligations issued or unconditionally guaranteed by the United States or any agency or any state thereof
having maturities of not more than one (1) year from the date of acquisition; (b) commercial paper maturing no more than one (1)
year after its creation and having the highest rating from either Standard & Poor’s Ratings Group or Moody’s Investors
Service, Inc.; (c) certificates of deposit issued; (d) accounts receivable in respect of government grants and contracts with governmental
entities, in each case of the types included as “accounts receivable” in the Borrower’s financial statements
in its periodic reports filed with the SEC; and (e) money market funds at least ninety-five percent (95%) of the assets of which
constitute Cash Equivalents of the kinds described in clauses (a) through (d) of this definition.

 

“Change in
Control” means any reorganization, recapitalization, consolidation or merger (or similar transaction or series of related
transactions) of any entity comprising Borrower, or sale or exchange of outstanding shares (or similar transaction or series of
related transactions) of any entity comprising Borrower, in each case in which the holders of such Borrower entity’s outstanding
shares immediately before consummation of such transaction or series of related transactions do not, immediately after consummation
of such transaction or series of related transactions, retain shares representing more than fifty percent (50%) of the voting power
of the surviving entity of such transaction or series of related transactions (or the parent of such surviving entity if such surviving
entity is wholly owned by such parent), in each case without regard to whether such Borrower entity is the surviving entity. Notwithstanding
the foregoing, the issuance by Borrower of its equity securities as part of a bona fide financing transaction, whether in a public
offering registered under the Securities Act or in a private offering exempt from the registration requirements of the Securities
Act, shall not constitute a “Change in Control.”

 

“Claims”
has the meaning given to such term in Section 11.10.

 

“Close of Business”
means 5:00 p.m., New York City time.

 

“Closing Date”
means the date of this Agreement.

 

“Closing Deliverables”
has the meaning given to such term in Section 4.1.

 

“Closing Expense
Charge” means reimbursement due to Lenders at the Closing Date for all reasonable and documented out-of-pocket costs and
expenses incurred by Lenders in negotiating and consummating the Term Loan, including reasonable and documented out-of-pocket legal
fees and expenses, in an aggregate amount not to exceed $60,000 (plus VAT, if applicable). Closing Expense Charge does not include
costs to be borne by Borrower relating to any filing, registration or recordation in order to create, in favor of Agent, a perfected
security interest in or lien upon the Collateral, including without limitation, UCC lien searches, preparation and filings of UCC
financing statements, any filing, registration or recordation with the United States Patent and Trademark Office or the United
States Copyright Office, or any similar office of a foreign jurisdiction, as applicable, and any deposit account control agreements
requested by the Lenders.

 

“Code”
means the Internal Revenue Code of 1986, as amended from time to time.

 

“Collateral”
means the property described in Section 3.1.

 

“Common Stock”
means the common stock, $0.01 par value per share, of Soligenix, Inc.

 

    2

     

    

 

“Confidential
Information” has the meaning given to it in Section 11.12.

 

“Contingent
Obligation” means, as applied to any Person, any direct or indirect liability, contingent or otherwise, of that Person with
respect to (i) any Indebtedness, dividend, letter of credit or other obligation of another, including any such obligation
directly or indirectly guaranteed, endorsed, co-made or discounted or sold with recourse by that Person, or in respect
of which that Person is otherwise directly or indirectly liable; (ii) any obligations with respect to undrawn letters of credit,
corporate credit cards or merchant services issued for the account of that Person; and (iii) all net obligations arising under
any interest rate, currency or commodity swap agreement, interest rate cap agreement, interest rate collar agreement, or other
agreement or arrangement designated to protect a Person against fluctuation in interest rates, currency exchange rates or commodity
prices; provided, however, that the term “Contingent Obligation” shall not include endorsements for collection or deposit
in the OCB or guaranties of leases in the OCB. The amount of any Contingent Obligation shall be deemed to be an amount equal to
the stated or determined amount of the primary obligation in respect of which such Contingent Obligation is made or, if not stated
or determinable, the maximum reasonably anticipated liability in respect thereof as determined by such Person in good faith; provided,
however, that such amount shall not in any event exceed the maximum amount of the obligations under the guarantee or other support
arrangement.

 

“Conversion
Notice” shall have the meaning set forth in Section 8.3.

 

“Conversion
Price” shall have the meaning given to such term in Section 8.2.

 

“Conversion
Shares” shall have the meaning given to such term in Section 8.3.

 

“Converted
Amount” shall have the meaning set forth in Section 8.3.

 

“Converting
Lender” shall have the meaning set forth in Section 8.3.

 

“Copyrights”
mean rights associated with works of authorship including copyrights, moral rights, rights of publicity, design rights, copyright
applications, copyright registrations, rights in mask works, rights existing under any copyright Laws and rights to prepare derivative
works, and all rights in data and databases.

 

“Covered Foreign
Subsidiaries” means each of Soligenix BioPharma Canada Incorporated, Soligenix UK Limited and Soligenix NE B.V., and each
other direct or indirect wholly owned foreign Subsidiary created after the Closing Date.

 

“Deposit Accounts”
means any “deposit accounts,” as such term is defined in the UCC.

 

“Environmental
Laws” has the meaning given to such term in Section 5.27.

 

“Equity Interests”
means, with respect to any Person, the capital stock, partnership or limited liability company interest, or other equity securities
or equity ownership interests of such Person.

 

“ERISA”
means the United States Employee Retirement Income Security Act of 1974, as amended, and the regulations promulgated thereunder.

 

“Event of Default”
has the meaning given to such term in Section 9.

 

“Exchange Act”
means the Securities Exchange Act of 1934, as amended.

 

“Excluded Account”
means any (a) any “zero balance” deposit account, (b) any deposit or securities account used exclusively for payroll,
employee benefits or employee taxes, the funds of which shall not exceed the amount required to pay the next payroll or other relevant
cycle, (c) cash collateral accounts and restricted accounts containing security deposits permitted pursuant to clauses (xiv) and
(xvii) of the definition of “Permitted Liens” so long as the aggregate balance of such accounts does not exceed $500,000,
and (d) de minimis accounts so long as the aggregate balance of all such accounts does not exceed $250,000.

 

    3

     

    

 

“Excluded Taxes”
means any of the following Taxes imposed on or with respect to a Lender or Agent or required to be withheld or deducted from a
payment to a Lender or Agent, (a) Taxes imposed on or measured by net income (however denominated), franchise Taxes, and branch
profits Taxes, in each case, (i) imposed as a result of such Lender or Agent being organized under the laws of, or having its principal
office or, in the case of any Lender, its applicable lending office located in, the jurisdiction imposing such Tax (or any political
subdivision thereof) or (ii) that are Other Connection Taxes, (b) in the case of a Lender, U.S. federal withholding Taxes imposed
on amounts payable to or for the account of such Lender with respect to an applicable interest in a Loan pursuant to a law in effect
on the date on which (i) such Lender acquires such interest in the Loan or (ii) such Lender changes its lending office, except
in each case to the extent that, pursuant to Section 2.7, amounts with respect to such Taxes were payable either to such Lender’s
assignor immediately before such Lender became a party hereto or to such Lender immediately before it changed its lending office,
(c) Taxes attributable to such Lender’s or Agent’s failure to comply with Section 2.9 or 2.10 and (d) any withholding
Taxes imposed under FATCA.

 

“FATCA”
means Section 1471 through 1474 of the Code, as of the date of this Agreement (or any amended or successor version that is substantively
comparable and not materially more onerous to comply with), any current or future regulations or official interpretations thereof
and any agreements entered into pursuant to Section 1471(b)(1) of the Code, and any applicable intergovernmental agreement with
respect thereto and applicable official implementing guidance thereunder.

 

“Financial
Statements” has the meaning given to such term in Section 7.1.

 

“GAAP”
means generally accepted accounting principles in the United States of America, as in effect from time to time.

 

“Governmental
Authority” is any nation or government, any state or other political subdivision thereof, any agency, authority, instrumentality,
regulatory body, court, central bank or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative
functions of or pertaining to government, any securities exchange and any self-regulatory organization.

 

“Health Care
Laws” has the meaning given to such term in Section 5.24.

 

“IFRS”
means International Financial Reporting Standards.

 

“Indebtedness”
means indebtedness of any kind, including (a) all indebtedness for borrowed money or the deferred purchase price of property
or services (excluding trade credit entered into in the OCB), including reimbursement and other obligations with respect to surety
bonds and letters of credit, (b) all obligations evidenced by notes, bonds, debentures or similar instruments, (c) all
capital lease obligations, and (d) all Contingent Obligations.

 

“Indemnified
Taxes” means (a) Taxes, other than Excluded Taxes, imposed on or with respect to any payment made by or on account of any
obligation of the Borrower under any Loan Document and (b) to the extent not otherwise described in (a), Other Taxes.

 

“Intellectual
Property” means any and all rights in and to all intellectual property and proprietary rights or assets arising or enforceable
under the Laws of the United States, any other country or jurisdiction, or any treaty regime, including the following: (i) Copyrights;
(ii) Trademarks; (iii) Patents; (iv) trade secrets and proprietary information (including preclinical, clinical and other data);
(v) all domain name registrations (“Domain Names”); (vi) applications for any of the foregoing and reissues, extensions,
or renewals thereof; (vii) scientific, financial, marketing, customer or other technical know-how; (viii) any products, technical
data or technology, including Software, that have been in the past or are currently being developed, manufactured, licensed to
a third party, distributed or sold by Borrower or which Borrower intends to sell, manufacture, license, or distribute in the future
(“Borrower Products”); (ix) any and all computer information technology systems, programs, applications, software,
SaaS, models and methodologies (including all source code, object code, firmware, programming tools and/or documentation), hardware,
firmware, networks, interfaces, and related systems and information technology assets machine-readable databases and compilations,
including any and all data and collections of data (“Software”); (x) social media accounts registered on well-known
social media platforms such as, but not limited to, Facebook, LinkedIn, Instagram, YouTube, and Twitter (“Social Media Accounts”);
(xi) all documentation and media relating to the above; (xii) all advertising materials, including all rights of publicity and
likeness; (xiii) all tangible embodiments of, and all intangible rights in, the foregoing, (xiv) all goodwill related to the
foregoing; and (xv) the right to sue for past, present, or future infringement and to collect and retain all damages and profits
related to the foregoing under the Laws of all jurisdictions.

 

    4

     

    

 

“Inventory”
means “inventory” as defined in Article 9 of the UCC.

 

“Investment”
means any beneficial ownership (including stock, partnership or limited liability company interests) of or in any Person, or any
loan, advance or capital contribution to any Person.

 

“Investment
Policy” is that certain investment policy of Borrower, approved by Borrower’s Board of Directors delivered to Agent
by Borrower.

 

“Joinder Agreements”
means for each Subsidiary, a completed and executed Joinder Agreement in substantially the form attached hereto as Exhibit B.

 

“Knowledge
of Borrower” and similar phrases mean the actual knowledge, after reasonable inquiry of their direct reports, of the chief
executive officer, chief financial officer, chief scientific officer, chief medical officer, chief operating office and general
counsel of the Borrower.

 

“Lender”
has the meaning given to such term in the preamble to this Agreement.

 

“Liabilities”
has the meaning given to such term in Section 6.3.

 

“License”
means any license of rights or interests from a third party to the Borrower, excluding licenses for Intellectual Property, “shrink-wrap,”
“browse-wrap,” “click-through,” and open source licenses, and any other non-exclusive licenses for third
party products or services that are made generally available to the public.

 

“Lien”
means any mortgage, deed of trust, pledge, hypothecation, assignment for security, security interest, encumbrance, levy, lien or
charge of any kind, whether voluntarily incurred or arising by operation of law or otherwise, against any property, any conditional
sale or other title retention agreement, and any lease in the nature of a security interest.

 

“Loan”
means the amounts made available by a Lender to Borrower under this Agreement.

 

“Loan Documents”
means this Agreement, any Notes, Pledge Agreement, Perfection Certificate, all UCC Financing Statements, any subordination agreement,
any deposit account control agreements and any other documents executed in connection with the Secured Obligations or the transactions
contemplated hereby, as the same may from time to time be amended, modified, supplemented or restated.

 

“Material Adverse
Effect” means a material adverse effect upon: (i) the business, operations, properties, assets or financial condition
of Borrower and its Subsidiaries taken as a whole; or (ii) the ability of Borrower to perform or pay the Secured Obligations
when due in accordance with the terms of the Loan Documents, or the ability of Agent or a Lender to enforce any of its rights or
remedies with respect to the Secured Obligations; or (iii) the value of the Collateral (taken as a whole and other than normal
depreciation) or Agent’s Liens on the Collateral or the priority of such Liens; provided, that in the case of clause (i),
the failure to successfully pass the Phase 3 trial for DOM-INNATE (“Dusquetide treatment in Oral Mucositis – by modulating
INNATE Immunity”) study for SGX942 (dusquetide) in the treatment of oral mucositis in head and neck cancer patients shall
not constitute a material adverse effect.

 

“Material Contract”
with respect to Borrower and its Subsidiaries each contract or agreement to which Borrower or any of its Subsidiaries is a party
(a) involving aggregate consideration payable to or by Borrower or any of its Subsidiaries of $500,000 or more in any fiscal year
or (b) that is a “material contract” (as such term is defined in Item 601(b)(10) of Regulation S-K of the SEC or required
to be disclosed on a current report on Form 8-K or other report filed with the SEC) and, (c) to the extent not otherwise covered
by the foregoing, each contract or agreement as to which the breach, nonperformance, cancellation or failure to renew by any party
thereto would reasonably be expected to have a Material Adverse Effect, excluding non-executive officer employment agreements.

 

“Maximum Rate”
has the meaning given to such term in Section 2.2.

 

    5

     

    

 

“Merger Event”
has the meaning given to such term in Section 8.6

 

“Money Laundering
Laws” has the meaning given to such term in Section 5.29.

 

“Nasdaq”
has the meaning given to such term in Section 8.7.

 

“Note(s)”
means a Term Note.

 

“OCB”
means in the ordinary course of business and shall include, without limitation, (i) collaboration or licensing transactions,
or options to enter into collaboration or licensing transactions, that are customary in Borrower’s industry and reasonably
related, incidental or ancillary to the business of Borrower, and (ii) arrangements to use Borrower’s research and development
capabilities to develop product candidates on behalf of third party pharmaceutical companies.

 

“OFAC”
means the U.S. Department of Treasury Office of Foreign Assets Control.

 

“OFAC Lists”
means, collectively, the Specially Designated Nationals and Blocked Persons List maintained by OFAC pursuant to Executive Order
No. 13224, 66 Fed. Reg. 49079 (Sept. 25, 2001) and/or any other list of terrorists or other restricted Persons maintained
pursuant to any of the rules and regulations of OFAC or pursuant to any other applicable Executive Orders.

 

“Other Connection
Taxes” means, with respect to any Lender or Agent, Taxes imposed as a result of a present or former connection between such
Lender or Agent and the jurisdiction imposing such Tax (other than connections arising from such Lender or Agent having executed,
delivered, become a party to, performed its obligations under, received payments under, received or perfected a security interest
under, engaged in any other transaction pursuant to or enforced any Loan Document, or sold or assigned an interest in any Loan
or Loan Document).

 

“Other Taxes”
means all present or future stamp, court or documentary, intangible, recording, filing or similar Taxes that arise from any payment
made under, from the execution, delivery, performance, enforcement or registration of, from the receipt or perfection of a security
interest under, or otherwise with respect to, any Loan Document, except any such Taxes that are Other Connection Taxes imposed
with respect to an assignment.

 

“Patents”
mean all patents, provisional applications, patent applications and patents issuing therefrom as well as any division, continuation
or continuation in part, reissue, extension, reexamination, certification, revival or renewal of any patent, all inventions and
subject matter related to such patents, in any and all forms.

 

“Perfection
Certificate” is that certain perfection certificate delivered by Borrower to Agent, dated as of the date hereof.

 

“Permitted
Indebtedness” means: (i) Indebtedness of Borrower in favor of a Lender or Agent arising under this Agreement or any
other Loan Document; (ii) Indebtedness existing on the date hereof which is disclosed in Schedule 1A; (iii) Indebtedness
of up to $100,000 outstanding at any time secured by a Lien described in clause (vii) of the defined term “Permitted
Liens,” provided such Indebtedness does not exceed the cost of the Equipment financed with such Indebtedness; (iv) Indebtedness
to trade creditors incurred in the OCB; (v) Indebtedness that also constitutes a Permitted Investment; (vi) Subordinated
Indebtedness; (vii) intercompany Indebtedness as long as each of the obligor and the obligee under such Indebtedness is a party
to this Agreement or has executed a Joinder Agreement; (viii) reimbursement obligations pursuant to (a) corporate credit cards
incurred in the OCB of up to $100,000 outstanding at any time and (b) letters of credit incurred in the OCB of up to $100,000 outstanding
at any time; (ix) Indebtedness in connection with workers compensation claims, disability, health or other employee benefits, obligations
with respect to severance payments and self-insurance obligations; (x) to the extent constituting Indebtedness, obligations in
respect of netting services or overdraft protection or otherwise in connection with Deposit Accounts in the OCB of up to $50,000
outstanding at any time; (xi) Indebtedness under future licensing agreements with unaffiliated third parties, on reasonable and
customary terms for agreements of such type, to which the Borrower may become a party in the OCB; (xii) extensions, refinancings
and renewals of any items of Permitted Indebtedness, provided that the principal amount is not increased or the terms modified
to impose materially more burdensome terms upon Borrower or its Subsidiary, as the case may be; and (xiii) other unsecured Indebtedness
in a principal amount not to exceed $150,000 in the aggregate at any time outstanding.

 

    6

     

    

 

“Permitted
Investment” means: (i) Investments existing on the date hereof which are disclosed in Schedule 1B; (ii) any Investments
permitted by Borrower’s Investment Policy, as amended from time to time, provided that any amendments to the Investment Policy
have been approved in writing by Agent (such approval not to be unreasonably withheld or delayed); (iii) Investments (including
debt obligations) received in connection with the bankruptcy or reorganization of customers or suppliers and in settlement of delinquent
obligations of, and other disputes with, customers or suppliers arising in the ordinary course of Borrower’s business; (iv) Investments
in existing or newly-formed Subsidiaries, provided that, each such Subsidiary is a party to this Agreement or has executed and
delivered to Agent a Joinder Agreement and such other documents as shall be reasonably requested by Agent; (v)  Investments
in joint ventures, collaboration agreements, strategic alliances and similar arrangements in the OCB, provided that any such cash
Investments by Borrower do not exceed $250,000 in the aggregate in any fiscal year; (vii) Investments consisting of the licensing
of technology, the development of technology, the providing of technical support and in-licensing of technology, provided
that any cash Investments by Borrower do not exceed $100,000 in the aggregate in any fiscal year; (viii) Investments by Borrower
or any Subsidiary that is a guarantor of the Secured Obligations in another Borrower or in a Subsidiary that is a guarantor of
the Secured Obligations; provided that any such Investments by Borrower in Covered Foreign Subsidiaries do not exceed $1,000,000
in the aggregate in any fiscal year; (ix) investments of up to $100,000 outstanding at any time consisting of (a) travel advances,
employee relocation loans and other employee loans and advances in the OCB and (b) non-cash loans to employees, officers or directors
relating to the purchase of equity securities of Borrower pursuant to employee stock purchase plans or arrangements approved by
Borrower’s board of directors; (x) investments consisting of Deposit Accounts; (xi) Investments consisting of repurchases
of equity interests permitted pursuant to Section 7.7; (xii) deposits of up to $100,000 outstanding at any time made to secure
the performance of leases, licenses or contracts in the OCB; and (xiii) additional Investments that do not exceed $100,000 in the
aggregate in any fiscal year.

 

“Permitted
Liens” means any and all of the following, which except as specifically permitted in Section 7.5, shall not include a Lien
for the benefit of a third party on Intellectual Property: (i) Liens in favor of Agent or a Lender; (ii) Liens existing
on the date hereof which are disclosed in Schedule 1C; (iii) Liens for taxes, fees, assessments or other governmental charges
or levies, either not delinquent or being contested in good faith by appropriate proceedings; provided, that Borrower maintains
adequate reserves therefor in accordance with GAAP or IFRS, as the case may be; (iv) Liens securing claims or demands of materialmen,
artisans, mechanics, carriers, warehousemen, landlords and other like Persons arising in Borrower’s OCB; provided, that the
payment thereof is not yet delinquent; (v) Liens arising from judgments, decrees or attachments in circumstances which do
not constitute an Event of Default hereunder; (vi) the following deposits, to the extent made in the OCB: deposits under worker’s
compensation, unemployment insurance, social security and other similar laws, or to secure the performance of bids, tenders or
contracts (other than for the repayment of borrowed money) or to secure indemnity, performance or other similar bonds for the performance
of bids, tenders or contracts (other than for the repayment of borrowed money) or to secure statutory obligations (other than Liens
arising under ERISA or environmental Liens) or surety or appeal bonds, or to secure indemnity, performance or other similar bonds;
(vii) Liens on equipment or Software or other Intellectual Property, or other capital assets, constituting purchase money
Liens and Liens in connection with capital leases, securing Indebtedness permitted in clause (iii) of “Permitted Indebtedness”;
(viii) Liens incurred in connection with Subordinated Indebtedness; (ix) leasehold interests in leases or subleases and licenses
granted in the OCB and not interfering in any material respect with the business of the licensor; (x) Liens in favor of customs
and revenue authorities arising as a matter of law to secure payment of custom duties that are promptly paid on or before the date
they become due; (xi) Liens on insurance proceeds securing the payment of financed insurance premiums that are promptly paid
on or before the date they become due (provided that such Liens extend only to such insurance proceeds and not to any other property
or assets); (xii) statutory, common law and contractual rights of set-off and other similar rights as to deposits of
cash and securities in favor of banks, other depository institutions and brokerage firms; (xiii) easements, zoning restrictions, rights-of-way and
similar encumbrances on real property imposed by law or arising in the OCB so long as they do not materially impair the value or
marketability of the related property; (xiv)  security deposits in connection with real property leases, in an aggregate amount
not to exceed $500,000 at any time; (xv) Liens in connection with operating leases in the equipment that is the subject of
such leases; (xvi) Permitted Transfers; (xvii) Pledges and deposits securing obligations pursuant to corporate credit cards
and letters of credit in an aggregate amount not to exceed $100,000 at any time; (xviii) Liens securing Subordinated Indebtedness;
(xix) any Lien existing on any property or asset prior to the acquisition thereof by Borrower or any Subsidiary or existing on
any property or asset of any Person that becomes a Subsidiary after the Effective Date prior to the time such Person becomes a
Subsidiary; (xx) Liens incurred in connection with the extension, renewal or refinancing of the Indebtedness secured by Liens of
the type described in clauses (i) through (xix) above; provided, that any extension, renewal or replacement Lien shall
be limited to the property encumbered by the existing Lien and the principal amount of the Indebtedness being extended, renewed
or refinanced (as may have been reduced by any payment thereon) does not increase, (xxi) Liens in connection with any netting or
set-off arrangement or under the applicable banking conditions; (xxii) Liens (a) on Equity Interests of joint ventures securing
capital contributions to or obligations of such joint ventures to the extent required in the organizational documents of such joint
ventures and not created in contemplation of this Agreement, and (b) consisting of customary rights of first refusal and tag, drag
and similar rights in joint venture agreements and investment documentation of non-wholly owned subsidiaries; and (xxiii) other
Liens securing obligations not to exceed the principal amount of $500,000 outstanding at any time.

 

    7

     

    

 

“Permitted
Transfers” means (i) sales of Inventory in the OCB; (ii) licenses, joint ventures, collaboration agreements, strategic
alliances and similar arrangements in the OCB providing for the licensing of Intellectual Property; provided that such licenses
do not result in a legal transfer of title of the licensed property and so long as after giving effect to each such license, Borrower
retains sufficient rights to use or benefit from such Intellectual Property as to enable it to conduct its business in the OCB;
(iii) dispositions of worn-out, obsolete or surplus Equipment in the OCB; (iv) use of cash in any manner not
prohibited by this Agreement; (v) transfers constituting Permitted Investments; (vi) transfers constituting Permitted
Liens; (vii) dispositions of Copyright rights in connection with publications in scientific journals; and (viii) other transfers
of assets having a fair market value of not more than $250,000 in the aggregate in any fiscal year.

 

“Person”
means any individual, sole proprietorship, partnership, joint venture, trust, unincorporated organization, association, corporation,
limited liability company, institution, other entity or government.

 

“Pledge Agreement”
means any pledge agreement executed by Borrower with respect to any equity in a Subsidiary or other investment property owned by
Borrower, made in favor of Agent to secure the Secured Obligations.

 

“Prepayment
Notice” has the meaning given to such term in Section 2.4.

 

“Quarter”
means the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 or December 31,
for so long as this Agreement is in effect.

 

“Receivables”
means (i) all of Borrower’s Accounts, Instruments, Documents, Chattel Paper, Supporting Obligations, letters of credit,
proceeds of any letter of credit, and Letter of Credit Rights, and (ii) all customer lists, Software, and business records
related thereto.

 

“Registration
Rights Agreement” means the Registration Rights Agreement dated on or about the date hereof by and among Borrower and Lenders.

 

“Regulatory
Agencies” has the meaning given to such term in Section 5.22.

 

“Regulatory
Licenses” has the meaning given to such term in Section 5.22.

 

“Rights of
Payment” has the meaning given to such term in Section 3.1.

 

“Rule 144”
has the meaning given to such term in Section 7.18.

 

“Rule 144 Certificate”
has the meaning given to such term in Section 7.18.

 

“Rule 144 Opinion”
has the meaning given to such term in Section 7.18.

 

“Sale Event”
has the meaning given to such term in Section 7.18.

 

“Sanctioned
Country” means, at any time, a country or territory which is the subject or target of any Sanctions.

 

    8

     

    

 

“Sanctioned
Person” means, at any time, (a) any Person listed in any Sanctions-related list of designated Persons maintained by
the Office of Foreign Assets Control of the U.S. Department of the Treasury or the U.S. Department of State, or by the United Nations
Security Council, the European Union or any EU member state, (b) any Person operating, organized or resident in a Sanctioned
Country or (c) any Person controlled by any such Person.

 

“Sanctions”
means economic or financial sanctions or trade embargoes imposed, administered or enforced from time to time by (a) the U.S.
government, including those administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury or the
U.S. Department of State, or (b) the United Nations Security Council, the European Union or Her Majesty’s Treasury of
the United Kingdom.

 

“SEC”
means the Securities and Exchange Commission.

 

“SEC Reports”
has the meaning given to such term in Section 5.12.

 

“Secured Obligations”
means Borrower’s obligations under this Agreement and any Loan Document, including any obligation to pay any amount now owing
or later arising.

 

“Securities
Act” means the Securities Act of 1933, as amended.

 

“Securities
Being Sold” has the meaning given to such term in Section 7.18.

 

“Subordinated
Indebtedness” means Indebtedness subordinated to the Secured Obligations in amounts and on terms and conditions satisfactory
to Agent in its reasonable discretion and subject to a subordination agreement in form and substance satisfactory to Agent in its
reasonable discretion.

 

“Subsidiary”
means an entity, whether a corporation, partnership, limited liability company, joint venture or otherwise, in which Borrower owns
or controls fifty percent (50.0%) or more of the outstanding voting securities, including the Covered Foreign Subsidiaries and
each entity listed on Schedule 5.15 hereto.

 

“Tax”
and “Taxes” means all present or future taxes, levies, imposts, duties, deductions, withholdings or other charges imposed
by any Governmental Authority, including any interest, additions to tax or penalties applicable thereto.

 

“Term Commitment”
means as to each Lender, the obligation of such entity, if any, to make payment on account of such entity’s portion of each
of the three loan facilities comprising the Term Loan to Borrower in a principal amount not to exceed the amount set forth under
the heading “Term Commitment” opposite such entity’s name on Schedule A.

 

“Term Loan”
shall have the meaning assigned to such term in the preamble of this Agreement.

 

“Term Loan
Interest Rate” means 8.47% per annum with respect to the Term Loan.

 

“Term Loan
Maturity Date” means the date which is the lapse of 54 months following the Closing Date.

 

“Term Note”
means a Secured Term Promissory Note in substantially the form of Exhibit A.

 

“Trademarks”
mean all trademarks, trade dress, service marks, trade names, icons, logos, slogans, and any other indicia of source or sponsorship
of goods and services, designs and logotypes related to the above, in any and all forms, all trademark registrations and applications
for registration related to such trademarks (including, but not limited to, intent to use applications), and all goodwill related
to the foregoing.

 

“UCC”
means the Uniform Commercial Code as the same is, from time to time, in effect in the State of New York; provided, that in the
event that, by reason of mandatory provisions of law, any or all of the attachment, perfection or priority of, or remedies with
respect to, Agent’s Lien on any Collateral is governed by the Uniform Commercial Code as the same is, from time to time,
in effect in a jurisdiction other than the State of New York, then the term “UCC” shall mean the Uniform Commercial
Code as in effect, from time to time, in such other jurisdiction solely for purposes of the provisions thereof relating to such
attachment, perfection, priority or remedies and for purposes of definitions related to such provisions.

 

    9

     

    

 

1.2. Unless
otherwise specified, all references in this Agreement or any Annex or Schedule hereto to a “Section,” “subsection,”
“Exhibit,” “Annex,” or “Schedule” shall refer to the corresponding Section, subsection, Exhibit,
Annex, or Schedule in or to this Agreement. Unless otherwise specifically provided herein, any accounting term used in this Agreement
or the other Loan Documents shall have the meaning customarily given such term in accordance with GAAP or IFRS, as the case may
be, and all financial computations hereunder shall be computed in accordance with GAAP or IFRS, as the case may be, consistently
applied. Unless otherwise defined herein or in the other Loan Documents, terms that are used herein or in the other Loan Documents
and defined in the UCC shall have the meanings given to them in the UCC.

 

SECTION 2. THE LOAN

 

2.1. Subject
to the terms and conditions of this Agreement, each Lender shall lend to Borrower its Term Commitment, totaling, for all Lenders,
the Term Loan. The Term Loan shall comprise of three loan facilities as set forth below.

 

(a) Initial
Loan. Subject to the terms and conditions of this Agreement, each Lender shall lend to Borrower its Term Commitment, totaling,
for all Lenders, $10,000,000 (the “Initial Loan”). The Initial Loan shall be provided in a single installment two (2)
Business Days after the Closing Date without any need for Borrower to deliver a notice or request, other than by provision of all
Closing Deliverables required to be delivered pursuant to Section 4.1, which delivery shall be deemed to constitute a borrowing
request by Borrower. Proceeds of the Initial Loan shall be deposited into a Deposit Account of Borrower existing as of the Closing
Date. The principal balance of the Initial Loan shall bear interest on the outstanding daily balance thereof from the actual funding
thereof at the Term Loan Interest Rate per annum based on a year consisting of 365 days. Borrower will pay interest on the Initial
Loan on the first Business Day of the first Quarter after the Closing Date and thereafter on the first day of every subsequent
Quarter, based on the Initial Loan principal amount outstanding at the end of the preceding Quarter. Borrower shall repay the Initial
Loan in ten (10) equal Quarterly installments beginning on the Amortization Date and continuing on the first Business Day of each
Quarter thereafter until the Term Loan Maturity Date. Accordingly, the entire outstanding Initial Loan principal balance and all
accrued but unpaid interest hereunder, shall be repaid by the Term Loan Maturity Date. Borrower shall make all payments under this
Agreement without setoff, recoupment or deduction (except as provided in Section 2.7) and regardless of any counterclaim.

 

(b) Credit
Line. Subject to the terms and conditions of this Agreement and to the closing of the Initial Loan, each Lender shall make available
to Borrower its Term Commitment, for all Lenders, totaling $5,000,000 (the “Credit Line”). The Credit Line shall be
available for withdrawal during a period of 12 months from the Closing Date (the “Credit Line Period”). Each portion
withdrawn under the Credit Line shall be provided within 14 days from a borrowing written request by Borrower. Upon the end of
the Credit Line Period, the amounts withdrawn shall be repayable in accordance with the terms hereof and the amounts not withdrawn
shall no longer be available for withdrawal. Proceeds of the Credit Line shall be deposited into a Deposit Account of Borrower.
The principal balance of the withdrawn Credit Line shall bear interest on the outstanding daily balance thereof from the actual
funding thereof at the Term Loan Interest Rate per annum based on a year consisting of 365 days. Borrower will pay interest on
the withdrawn Credit Line on the first Business Day of the first Quarter after the initial funding date of the Credit Line and
thereafter on the first day of every subsequent Quarter, based on the withdrawn Credit Line principal amount outstanding in the
preceding Quarter. In addition, until the end of the Credit Line Period, Borrower shall pay a fee of 1.0% per annum based on a
year consisting of 365 days on the daily average amount not withdrawn under the Credit Line. Borrower will pay the fee on the average
amount not withdrawn under the Credit Line on the first Business Day following the end of each Quarter, starting on the first Business
Day following the end of the Quarter in which the Closing takes place and thereafter on the first day of every subsequent Quarter,
based on the amount not withdrawn under the Credit Line in the preceding Quarter. Borrower shall repay the withdrawn Credit Line
in ten (10) equal Quarterly installments beginning on the Amortization Date and continuing on the first Business Day of each Quarter
thereafter until the Term Loan Maturity Date. Accordingly, the entire withdrawn and outstanding Credit Line principal balance and
all accrued but unpaid interest hereunder, shall be repaid by the Term Loan Maturity Date. Borrower shall make all payments under
this Agreement without setoff, recoupment or deduction (except as provided in Section 2.7) and regardless of any counterclaim.

 

    10

     

    

 

(c) Third
Installment Loan. Subject to the terms and conditions of this Agreement and to the closing of the Initial Loan, each Lender
shall make available to Borrower its Term Commitment, totaling, for all Lenders, $5,000,000 (the “Third Installment Loan”).
The Third Installment Loan shall be available for withdrawal in full by the Borrower upon Borrower’s achievement of the following
milestone by no later than 15 months from the Closing Date: the filing of a new Drug Application with the FDA for SGX301, which
shall be deemed to occur on the date of initial filing with the FDA (the “Third Installment Milestone”). If withdrawn,
the Third Installment Loan shall be provided within 14 days from a borrowing written request by Borrower, provided that the written
request shall be accompanied by a certificate of the Chief Financial Officer confirming Borrower’s achievement of the Milestone.
The Third Installment Loan shall be repayable in accordance with the terms hereof. Proceeds of the Third Installment Loan shall
be deposited into a Deposit Account of Borrower. The principal balance of the withdrawn Third Installment Loan shall bear interest
on the outstanding daily balance thereof from the actual funding thereof at the Term Loan Interest Rate per annum based on a year
consisting of 365 days. Borrower will pay interest on the withdrawn Third Installment Loan on the first Business Day of the first
Quarter after the funding date of the Third Installment Loan and thereafter on the first day of every subsequent Quarter, based
on the withdrawn Third Installment Loan principal amount outstanding in the preceding Quarter. In addition, if the Third Installment
Loan is withdrawn, together with the first payment of interest on account of the Third Installment Loan, Borrower shall pay a fee
of 1.0% per annum of the Third Installment Loan, on account of the period between the Closing Date and the funding of the Third
Installment Loan. Borrower shall repay the withdrawn Third Installment Loan in ten (10) equal Quarterly installments beginning
on the Amortization Date and continuing on the first Business Day of each Quarter thereafter until the Term Loan Maturity Date.
Accordingly, the entire withdrawn and outstanding Third Installment Loan principal balance and all accrued but unpaid interest
hereunder, shall be repaid by the Term Loan Maturity Date. Borrower shall make all payments under this Agreement without setoff,
recoupment or deduction (except as provided in Section 2.7) and regardless of any counterclaim.

 

(d) Each
entity comprising Borrower shall guarantee and be jointly and severally liable for repayment of each of the three facilities comprising
the Term Loan as described above and all other obligations of Borrower, and each entity comprising Borrower, hereunder, without
regard to whether such entity drew down the proceeds of any such facility or incurred any such other obligations, in each case,
to the maximum extent permitted under applicable law for each such entity, including laws with respect to fraudulent conveyances,
financial assistance or similar concepts under each applicable jurisdiction shall not be released, discharged or in any way affected
by, any circumstance or condition (whether or not such Borrower shall have any knowledge or notice thereof) whatsoever which might
constitute a legal or equitable discharge or defense (other than payment in full).

 

(e) Such
Borrower unconditionally and irrevocably waives, to the fullest extent permitted by applicable law: (i) notice of any of the matters
referred to above; (ii) the right to require Lenders or Agent to proceed against any other Borrower liable on the Secured Obligations,
to proceed against or exhaust any security held by any other Borrower, or to pursue any other remedy in each Lender’s or
Agent’s power; (iii) the right to have the property of any other Borrower first applied to the discharge of the obligations
hereunder or under the other documents contemplated hereby and (iv) until such time that all Secured Obligations (other than inchoate
indemnification or reimbursement obligations or other obligations which, by their terms, survive termination of this Agreement)
have been paid in full, any and all rights it may now or hereafter have under any agreement or at law or in equity (including,
without limitation, any law subrogating such Borrower to the rights of Lenders) to assert any claim against or seek contribution,
indemnification or any other form of reimbursement from any other Borrower under or in connection with this Agreement or otherwise.
The Lenders may, at the election of Lenders who provided at least 60% of the outstanding Secured Obligations (the “Required
Lenders”), exercise any right or remedy they may have against a Borrower entity without affecting or impairing in any way
the liability of any other entity comprising Borrower hereunder and such Borrower waives, to the fullest extent permitted by applicable
law, any defense arising out of the absence, impairment or loss of any right of reimbursement, contribution or subrogation or any
other right or remedy of such Borrower against any other Borrower. Such Borrower waives any defense arising by reason of any disability
or other defense of another entity comprising Borrower or by reason of the cessation for any cause whatsoever of the liability,
either in whole or in part, of another Borrower to Lenders or Agent, and such Borrower assumes the responsibility for being and
keeping informed of the financial condition of each other Borrower and of all other circumstances bearing upon the risk of nonpayment
of the obligations under this Agreement and the other Loan documents and agrees that Lenders or Agent shall not have any duty to
advise such Borrower of any such information or changes thereto; and that Lenders and Agent have not made any representations with
respect thereto.

 

    11

     

    

 

At any time, without
terminating, affecting or impairing the validity of the obligations of a Borrower hereunder, Lenders or Agent may deal with another
Borrower in the same manner and as fully as if the obligations of such Borrower did not exist and shall be entitled, among other
things, to grant each other Borrower, without notice or demand and without affecting such Borrower’s liability hereunder,
such extensions of time to perform, renew, compromise, accelerate or otherwise change the time for payment of or otherwise change
the terms of this Agreement and the indebtedness hereunder, or to waive any obligation of another Borrower to perform, any act
or acts as the Required Lenders may deem advisable.

 

2.2. Maximum
Interest. Notwithstanding any provision in this Agreement, the Notes, or any other Loan Document, it is the parties’ intent
not to contract for, charge or receive interest at a rate that is greater than the maximum rate permissible by law that a court
of competent jurisdiction shall deem applicable hereto (the “Maximum Rate”). If a court of competent jurisdiction shall
finally determine that Borrower has actually paid to Lenders an amount of interest in excess of the amount that would have been
payable if all of the Secured Obligations had at all times borne interest at the Maximum Rate, then such excess interest actually
paid by Borrower shall be applied as follows: first, to the payment of the Secured Obligations consisting of the outstanding principal;
second, after all principal is repaid, to the payment of Lender’s accrued interest, costs, expenses, professional fees and
any other Secured Obligations; and third, after all Secured Obligations are repaid, the excess (if any) shall be refunded to Borrower.

 

2.3. Default
Interest. In the event any payment is not paid on the scheduled payment date, subject to applicable grace periods, if any, an amount
equal to three percent (3.0%) of the past due amount shall be payable on demand. In addition, upon the occurrence and during the
continuation of an Event of Default hereunder, all outstanding principal hereunder, shall, at Agent’s option, bear interest
at a rate per annum equal to the rate set forth in Section 2.1(b) plus three percent (3.0%) per annum.

 

2.4. Prepayment.
Other than the quarterly amortization payments made pursuant to Section 2.1(c), the Borrower may only prepay the Term Loan in accordance
with this Section 2.4. At its option, following 18 months from the Closing Date, upon at least fourteen (14) Business Days
prior written notice to Agent (“Prepayment Notice”), Borrower may prepay an amount of not less than US$500,000 or all
of the then outstanding principal balance and all accrued and unpaid interest thereon, together with a prepayment charge equal
to one percent (1%) of the amount being prepaid (each, a “Prepayment Charge”). Borrower agrees that the Prepayment
Charge is a reasonable calculation of Lender’s lost profits in view of the difficulties and impracticality of determining
actual damages resulting from an early repayment of the Term Loan or a portion thereof as aforesaid. Any such early repayments
shall be applied to the required amortization payments in reverse chronological order (i.e., the payments on or closest to the
Term Loan Maturity shall be paid first). In a case where a Lender has submitted a Conversion Notice to Borrower within the 14 Business
Day period following receipt of the Prepayment Notice, no prepayment shall be allowed prior to conversion as requested in such
Conversion Notice and the Conversion Notice shall prevail. The Prepayment Notice shall apply to any outstanding Term Loan amount
remaining, if any, after conversion as specified in the Conversion Notice. In addition, if the Borrower has received a written
offer for a proposed Change in Control (“CoC Offer”), prepayment shall not be permitted. However, if the CoC Offer
does not lead to an executed transaction within sixty (60) days of receipt of the initial written offer, or the Borrower terminates
the negotiations on the CoC Offer, then prepayment shall be allowed following the lapse of such period or termination, as applicable,
provided however that in the event that the Borrower has yet to execute a definitive agreement with respect to the CoC Offer but
active negotiations with respect to the CoC Offer are ongoing, the 60 day period will be extended by an additional period agreed
between the Borrower and the Lenders in good faith. For the avoidance of doubt, (i) following any prepayment in accordance with
the foregoing, the Term Loans remaining outstanding shall bear interest at the Term Loan Interest Rate and (ii) the Borrower shall
have a 14 Business Day period following the end of the period described in the preceding sentence to submit a Conversion Notice,
if not previously submitted.

 

2.5. Notes.
If so requested by a Lender by written notice to Borrower, then Borrower shall execute and deliver to Lender (and/or, if applicable
and if so specified in such notice, to any Person who is a permitted assignee of Lender pursuant to Section 11.13), promptly
after Borrower’s receipt of such notice, one or more Term Notes to evidence Lender’s Term Loans.

 

2.6. Pro
Rata Treatment. Each payment (including prepayment) on account of any fee and any reduction of the Term Loans shall be made pro
rata according to the Term Commitments of the relevant Lender.

 

    12

     

    

 

2.7. Withholding.
All payment of interest or principal payable by Borrower hereunder and under the other Loan Documents shall be paid without any
deduction or withholding for any Taxes, unless required by law. If Borrower is required by law to deduct or withhold from a payment
to be made by Borrower, then Borrower shall be entitled to make such deduction or withholding and shall timely pay the full amount
deducted or withheld to the relevant Governmental Authority in accordance with applicable law and, if such Tax is an Indemnified
Tax, then the sum payable by Borrower shall be increased as necessary so that after such deduction or withholding has been made
(including such deductions and withholdings applicable to additional sums payable under this Section) the applicable Lender or
Agent receives an amount equal to the sum it would have received had no such deduction or withholding been made. The Borrower shall
indemnify each Lender or Agent, within 10 days after demand therefor, for the full amount of any Indemnified Taxes (including
Indemnified Taxes imposed or asserted on or attributable to amounts payable under this Section) payable or paid by such Lender
or Agent or required to be withheld or deducted from a payment to such Lender or Agent and any reasonable expenses arising therefrom
or with respect thereto, whether or not such Indemnified Taxes were correctly or legally imposed or asserted by the relevant Governmental
Authority.

 

2.8. Payment
of Other Taxes by Borrower. Borrower shall timely pay to the relevant Governmental Authority in accordance with applicable law,
or at the option of the Agent timely reimburse it for the payment of, any Other Taxes.

 

2.9. Status
of Lender. Agent and Lenders agree that:

 

(a) Any
Lender that is entitled to an exemption from or reduction of withholding Tax with respect to payments made under any Loan Document
shall deliver to Borrower and Agent, at the time or times reasonably requested by Borrower or Agent, such properly completed and
executed documentation reasonably requested by Borrower or Agent as will permit such payments to be made without withholding or
at a reduced rate of withholding.

 

(b) Each
Lender agrees that if any form or certification it previously delivered expires or becomes obsolete or inaccurate in any respect,
it shall update such form or certification or promptly notify Borrower and Agent in writing of its legal inability to do so.

 

2.10. FATCA
Information.

 

(a) Subject
to paragraph (c) below, each party shall, within ten (10) business days of a reasonable request by another party confirm to that
other party whether it is entitled to receive payments free from any deduction or withholding from a payment hereunder required
by FATCA (a “FATCA Deduction” and a “FATCA Exempt Party” or not a FATCA Exempt Party). Additionally, it
will supply to that other party such forms, documentation and other information relating to its status under FATCA as that other
party reasonably requests for the purposes of that other party’s compliance with FATCA and supply to that other party such
forms, documentation and other information relating to its status as that other Party reasonably requests for the purposes of that
other party’s compliance with any other law, regulation, or exchange of information regime.

 

(b) If
a party confirms to another party pursuant to paragraph (a) above that it is a FATCA Exempt Party and it subsequently becomes aware
that it is not or has ceased to be a FATCA Exempt Party, that party shall notify that other party reasonably promptly.

 

(c) Paragraph
(a) above shall not oblige any party to do anything that would or might in its reasonable opinion constitute a breach of (i) any
law or regulation, (ii) any fiduciary duty or (iii) any duty of confidentiality.

 

(d) If
a party fails to confirm whether or not it is a FATCA Exempt Party or to supply forms, documentation or other information requested
in accordance with paragraph (a) above (including, for the avoidance of doubt, where paragraph (c) above applies), then such party
shall be treated for the purposes of the Loan Documents (and payments under them) as if it is not a FATCA Exempt Party until such
time as the party in question provides the requested confirmation, forms, documentation or other information.

 

(e) If
a Borrower is a “United States person” within the meaning of Code Section 7701(a)(30) (a “US Tax Obligor”)
or Agent reasonably believes that its obligations under FATCA or any other applicable law or regulation require it, each Lender
shall, within ten business days of (i) where a Borrower is a US Tax Obligor and such Lender is a Party as a Lender at the date
of this Agreement, the date of this Agreement, (ii) where a Borrower is a US Tax Obligor on a date on which any other bank becomes
a Party as a bank, that date, (iii) the date a new US Tax Obligor accedes as a Borrower or (iv) where a Borrower is not a US Tax
Obligor, the date of a request from Agent, supply to Agent:

 

A.  a
withholding certificate on Form W-8, Form W-9 or any other relevant form; or

 

    13

     

    

 

B. any
withholding statement or other document, authorization or waiver as Agent may require to certify or establish the status of such
bank under FATCA or that other law or regulation.

 

(f) Agent
shall provide any withholding certificate, withholding statement, document, authorization or waiver it receives from a Lender pursuant
to paragraph (e) above to the relevant Borrower.

 

(g) If
any withholding certificate, withholding statement, document, authorization or waiver provided to Agent by a Lender pursuant to
paragraph (e) above is or becomes materially inaccurate or incomplete, that bank shall promptly update it and provide such updated
withholding certificate, withholding statement, document, authorization or waiver to Agent unless it is unlawful for such entity
to do so (in which case the bank shall promptly notify Agent). Agent shall provide any such updated withholding certificate, withholding
statement, document, authorization or waiver to the relevant Borrower.

 

(h) Agent
may rely on any withholding certificate, withholding statement, document, authorization or waiver it receives from a Lender pursuant
to paragraph (e) or (g) above without further verification. Agent shall not be liable for any action taken by it under or in connection
with paragraphs (e), (f) or (g) above.

 

2.11. FATCA
Deduction. Each party may make any FATCA Deduction it is required to make by FATCA, and any payment required in connection with
that FATCA Deduction, and no party shall be required to increase any payment in respect of which it makes such a FATCA Deduction
or otherwise compensate the recipient of the payment for that FATCA Deduction. Each party shall promptly, upon becoming aware that
it must make a FATCA Deduction (or that there is any change in the rate or the basis of such FATCA Deduction), notify the party
to whom it is making the payment.

 

2.12. Original
Issue Discount. The parties acknowledge and agree that the Term Loan may be issued with original issue discount (“OID”)
for U.S. federal income tax purposes in accordance with the requirements under the Code. The parties will treat and report all
payments made pursuant to this Agreement consistent with the foregoing characterization for all tax purposes. Borrower shall provide
to Lenders the issue price, the amount of OID, the issue date, the yield to maturity, and the comparable yield and projected payment
schedule and any other information necessary for Lenders to determine the OID on the Loan.

 

SECTION 3. SECURITY INTEREST

 

3.1. As
security for the prompt and complete payment when due (whether on the payment dates or otherwise) of all the Secured Obligations,
Borrower grants to Agent a security interest, senior to any current and future debts and to any security interest (subject to Permitted
Liens), in all of Borrower’s right, title, and interest in, to the following personal property of Borrower (except as set
forth herein) whether now owned or hereafter acquired (collectively, the “Collateral”): (a) Receivables; (b) Equipment;
(c) Fixtures; (d) General Intangibles (other than Intellectual Property); (e) Inventory; (f) Investments; (g) Deposit Accounts;
(h) Cash; (i) Goods; (j) Licenses; (k) franchise agreements, (l) commercial tort claims; and all other tangible and intangible
personal property of Borrower whether now or hereafter owned or existing; and, to the extent not otherwise included, all Proceeds
of each of the foregoing and all accessions to, substitutions and replacements for, and rents, profits and products of each of
the foregoing. Notwithstanding any of the foregoing, the Collateral shall not under any circumstances include, and no security
interest is granted in, any Intellectual Property; provided, however, that the Collateral does and shall include all (i) Accounts
and general intangibles that consist of rights to payment, and (ii) proceeds from any form whatsoever from commercialization or
monetization of, or the generation of any revenues or other consideration from, Borrower’s owned or licensed Intellectual
Property, including from the distribution or licensing of, or sale or invitation to license, assertion, litigation, enforcement
in any form, or disposition of all or any part, or rights in, such Intellectual Property (the “Rights to Payment”).
Notwithstanding the foregoing, if a U.S. Bankruptcy Court (or a bankruptcy or similar court in another jurisdiction) holds that
a security interest in the underlying Intellectual Property is necessary to have a security interest in the Rights to Payment,
then the Collateral shall automatically, and effective as of the date of this Agreement, include Borrower’s owned Intellectual
Property to the extent necessary to permit perfection of Agent’s security interest in the Rights to Payment. Upon request
by Agent, Borrower shall produce, execute and file any document (including UCC Financing Statements), and make any arrangement
using its best efforts as reasonably requested by Agent to perfect and establish Agent’s security interest in the Collateral,
and to the extent Borrower does not promptly make any such filing (including on the Closing Date), Agent is authorized to make
such filing including all UCC Financing Statements deemed by Agent to be necessary to perfect Agent’s security interest in
the Collateral.

 

    14

     

    

 

3.2. Notwithstanding
the broad grant of the security interest set forth in Section 3.1, above, the Collateral shall not include (a) any Intellectual
Property except to the extent expressly described in Section 3.1 above, (b) nonassignable licenses or contracts, which by their
terms require the consent of the licensor thereof or another party (but only to the extent such prohibition on transfer is enforceable
under applicable law, including, without limitation, Sections 9-406, 9-407 and 9-408 of the UCC), (c) any leasehold real property
interest, license, lease or other contract or agreement or any property subject to a purchase money security interest or similar
arrangement to the extent that a grant of a security interest therein would violate or invalidate such lease, license, contract
or agreement or purchase money arrangement or create a right of termination in favor of any other party thereto (but only to the
extent such prohibition on transfer or grant of a security interest is enforceable under applicable law, including, without limitation,
Sections 9406, 9407 and 9408 of the UCC), (d) any property to the extent that, and for as long as, such grant of a security interest
is prohibited by any applicable law, rule or regulation; provided that the foregoing exclusion in this clause (e) shall in no way
be construed (i) to apply to the extent that any described prohibition is unenforceable under Section 9-406, 9-407 or 9-408 of
the UCC or other applicable law or (ii) to apply to the extent that any consent or waiver has been obtained, or is hereafter obtained,
that would permit Agent’s security interest or Lien notwithstanding the prohibition on the grant of a security interest in
such property, (f) Excluded Accounts, (g) motor vehicles or other assets in which a security interest may be perfected only though
compliance with a certificate of title statute, (h) any Cash or certificates of deposit securing reimbursement obligations permitted
under this Agreement, or (i) any property or asset with respect to which Agent shall have determined in its reasonable discretion
that the cost of obtaining, perfecting or maintaining a security interest in such property or asset exceeds the value of the security
afforded thereby.

 

3.3. If
this Agreement is terminated in accordance with its terms, Agent’s Lien in the Collateral shall continue until the Secured
Obligations (other than inchoate indemnity obligations or other obligations which, by their terms, survive termination of this
Agreement) are satisfied in full, and at such time Agent’s security interest in the Collateral shall automatically and immediately
be terminated and released without further action by any party and all rights therein shall automatically revert to Borrower. Agent
shall execute such documents and take such other steps as are reasonably requested by Borrower to accomplish or evidence the foregoing,
all at Borrower’s sole cost and expense.

 

SECTION 4. CONDITIONS PRECEDENT TO
LOAN

 

The obligations of
Lenders to make the Loan hereunder are subject to the satisfaction by Borrower of the following conditions:

 

4.1. On
or prior to the Closing Date, Borrower shall have delivered to Agent the following (“Closing Deliverables”):

 

(a) executed
copies of the Loan Documents and all other documents and instruments reasonably requested by Agent to effectuate the transactions
contemplated hereby or to create and perfect the Liens of Agent with respect to all Collateral (except as provided in Section 7.20),
in all cases in form and substance reasonably acceptable to Agent;

 

(b) copy
of resolutions of Borrower’s board of directors evidencing approval of the Loan and other transactions evidenced by the Loan
Documents;

 

(c) copies
of the Certificate of Incorporation and the Bylaws, or other organizational documents, as amended through the Closing Date, of
Borrower;

 

    15

     

    

 

(d) a
certificate of good standing for Borrower from its state of incorporation and similar certificates from all other jurisdictions
in which it is qualified to do business, except where the failure to be so qualified could not reasonably be expected to have a
Material Adverse Effect;

 

(e) to
the extent invoiced to Borrower prior to the Closing Date, payment of the Closing Expense Charge (if not paid prior to the Closing
Date). If not invoiced prior to Closing Date, Closing Expense Charge and out-of-pocket costs associated with filings required to
perfect Agent’s security interest or diligence searches with Governmental Authorities will be paid following the Closing
Date, within ten (10) Business Days from receipt of invoice;

 

(f) [reserved];

 

(g) each
document (including any UCC financing statement) required by this Agreement, any related agreement or under law or reasonably requested
by Agent to be filed, registered or recorded in order to create, in favor of Agent, a perfected security interest in or lien upon
the Collateral shall be in proper form to be filed, registered or recorded in each jurisdiction in which the filing, registration
or recordation thereof is so required or requested;

 

(h) executed
copy of a Registration Rights Agreement; and

 

(i) a
Compliance Certificate substantially in the form attached hereto as Exhibit C, executed by Borrower.

 

4.2. No
Default. As of the Closing Date and the date any Term Loan is made, (i) no fact or condition exists that (or could, with the
passage of time, the giving of notice, or both) constitutes an Event of Default and (ii) no event that has had or could reasonably
be expected to have a Material Adverse Effect has occurred and is continuing.

 

SECTION 5. REPRESENTATIONS
AND WARRANTIES OF BORROWER

 

Borrower represents and warrants
that, as of the Closing Date and the date any Term Loan is made:

 

5.1. Corporate
Status. Each entity comprising Borrower is a company duly organized, legally existing and, to the extent relevant in the applicable
jurisdiction, in good standing under the laws of its jurisdiction of incorporation, and is duly qualified as a foreign corporation
or limited liability company in all jurisdictions in which the nature of its business or location of its properties require such
qualifications, except where the failure to be so qualified would not reasonably be expected to have a Material Adverse Effect.
Borrower’s present name, former names within the last five (5) years (if any), owned and leased locations, place of formation,
tax identification number and organizational identification number are correctly set forth in Schedule 5.1, as may be updated by
Borrower from time to time in a written notice provided to Agent after the Closing Date.

 

5.2. Collateral.
Borrower owns the Collateral free of all Liens, except for Permitted Liens. Borrower has the power and authority to grant to Agent
a Lien in the Collateral as security for the Secured Obligations.

 

5.3. Consents.
Borrower’s execution, delivery and performance of this Agreement and all other Loan Documents, (i) have been duly authorized
by all necessary corporate action of Borrower, (ii) will not result in the creation or imposition of any Lien upon the Collateral,
other than Permitted Liens and the Liens created by this Agreement and the other Loan Documents, (iii) do not violate any
provisions of Borrower’s Certificate of Incorporation, bylaws, or any material law, regulation, order, injunction, judgment,
decree or writ to which Borrower is subject, (iv) except as described on Schedule 5.3, do not violate any Material Contract
or require the consent or approval of any other Person which has not already been obtained, in each case, except as would not reasonably
be expected to result in a Material Adverse Effect. The individual or individuals executing the Loan Documents on behalf of Borrower
are duly authorized to do so.

 

5.4. Material
Adverse Effect. No event that has had or could reasonably be expected to have a Material Adverse Effect has occurred and is continuing.
Borrower is not aware of any event likely to occur that is reasonably expected to result in a Material Adverse Effect.

 

    16

     

    

 

5.5. Actions
Before Governmental Authorities. Except as described on Schedule 5.5, there are no actions, suits or proceedings at law or in equity
or by or before any Governmental Authority now pending or, to the knowledge of Borrower, threatened in writing against or affecting
Borrower or its property, that would reasonably be expected to result in a Material Adverse Effect.

 

5.6. Laws.
Neither Borrower nor any of its Subsidiaries is in violation of any material law, rule or regulation, or in default with respect
to any judgment, writ, injunction or decree of any Governmental Authority, where such violation or default is reasonably expected
to result in a Material Adverse Effect. Borrower is not in default in any material respect under any provision of any Material
Agreement to which it is a party or by which it is bound, which default would reasonably be expected to have a Material Adverse
Effect.

 

Neither Borrower
nor any of its Subsidiaries is registered or required to register as an “investment company” or a company “controlled”
by an “investment company” under the Investment Company Act of 1940, as amended. Neither Borrower nor any of its Subsidiaries
is engaged as one of its important activities in extending credit for margin stock (under Regulations X, T and U of the Federal
Reserve Board of Governors). Borrower and each of its Subsidiaries has complied in all material respects with applicable provisions
of the Federal Fair Labor Standards Act. Neither Borrower nor any of its Subsidiaries is a “holding company” or an
“affiliate” of a “holding company” or a “subsidiary company” of a “holding company”
as each term is defined and used in the Public Utility Holding Company Act of 2005. Neither Borrower’s nor any of its Subsidiaries’
properties or assets has been used by Borrower or such Subsidiary or, to Borrower’s knowledge, by previous Persons, in disposing,
producing, storing, treating, or transporting any hazardous substance other than in material compliance with applicable laws. Borrower
and each of its Subsidiaries has obtained all consents, approvals and authorizations of, made all declarations or filings with,
and given all notices to, all Governmental Authorities that are necessary to continue their respective businesses as currently
conducted, except to the extent that the failure to obtain, make or give any of the foregoing would not reasonably be expected
to have a Material Adverse Effect.

 

None of Borrower,
any of its Subsidiaries, or to Borrower’s knowledge any of Borrower’s or its Subsidiaries’ Affiliates or any
of their respective agents acting or benefiting in any capacity in connection with the transactions contemplated by this Agreement
is (i) in violation of any Anti-Terrorism Law, (ii) engaging in or conspiring to engage in any transaction that evades
or avoids, or has the purpose of evading or avoiding or attempts to violate, any of the prohibitions set forth in any Anti-Terrorism
Law, or (iii) is a Blocked Person. None of Borrower, any of its Subsidiaries, or to the knowledge of Borrower and any of its
Affiliates or agents, acting or benefiting in any capacity in connection with the transactions contemplated by this Agreement,
(x) conducts any business or engages in making or receiving any contribution of funds, goods or services to or for the benefit
of any Blocked Person, or (y) deals in, or otherwise engages in any transaction relating to, any property or interest in property
blocked pursuant to Executive Order No. 13224, any similar executive order or other Anti-Terrorism Law. None of the funds
to be provided under this Agreement will be used, directly or indirectly, (a) for any activities in violation of any applicable
anti-money laundering, economic sanctions and anti-bribery laws and regulations laws and regulations or (b) for any payment
to any governmental official or employee, political party, official of a political party, candidate for political office, or anyone
else acting in an official capacity, in order to obtain, retain or direct business or obtain any improper advantage, in violation
of the United States Foreign Corrupt Practices Act of 1977, as amended.

 

5.7. Information
Correct and Current. No written information, report, Advance Request, financial statement, exhibit or schedule furnished, by or
on behalf of Borrower to Agent in connection with any Loan Document or included therein or delivered pursuant thereto contained,
or, when taken as a whole, contains any material misstatement of fact or, when taken together with all other such information or
documents, omitted, omits or will omit to state any material fact necessary to make the statements therein, in the light of the
circumstances under which they were, are or will be made, not materially misleading at the time such statement was made or deemed
made (it being understood that financial and business projections are subject to significant uncertainties and contingencies, many
of which are beyond the control of Borrower, that no assurance is given that any particular projections will be realized, and that
actual results may differ, and such differences may be material). Additionally, any and all financial or business projections provided
by Borrower to Agent, whether prior to or after the date hereof, shall be (i) provided in good faith and based on the most
current data and information available to Borrower, and (ii) the most current of such projections provided to Borrower’s
Board of Directors (it being understood that such projections are subject to significant uncertainties and contingencies, many
of which are beyond the control of Borrower, that no assurance is given that any particular projections will be realized, and that
actual results may differ, and such differences may be material).

 

    17

     

    

 

5.8. Intellectual
Property.

 

(a) Schedule
5.8(a) is a true, correct and complete list of each of Borrower’s owned (i) Patents; (ii) registered Trademarks; (iii) registered
Copyrights; (iv) Domain Names; (v) Social Media Accounts, together with applications for any of the foregoing, and listing all
application or registration numbers, as applicable. Schedule 5.8(a) also includes lists of (vi) all Borrower’s proprietary
databases, (vii) Borrower’s proprietary Software, and (viii) licenses of Intellectual Property by third parties to Borrower
or by Borrower to third parties, in each case as of the date hereof. Each of the registered Intellectual Property owned by Borrower
is valid, subsisting, enforceable and in full force and effect, and each of the Intellectual Property licensed from third parties
is, to the Borrower’s knowledge, valid, subsisting, enforceable and in full force and effect. No Intellectual Property owned
or licensed by Borrower has been judged, by a decision of a court of competent jurisdiction, invalid or unenforceable, in whole
or in part. The Intellectual Property set forth in Schedule 5.8(a) constitutes all of the Intellectual Property necessary for conduct
the business as currently conducted.

 

(b) Borrower
has good and valid title to, or otherwise possesses sufficient rights to use all Intellectual Property owned, used or held for
use in the Borrower’s business as currently conducted. Except for Intellectual Property owned by third parties and licensed
to Borrower for use in the business, no Person other than Borrower has any right or interest of any kind in or with respect to
the Intellectual Property owned, used or held for use in the business, or any rights to sell, license, lease, transfer or use or
otherwise exploit such Intellectual Property.

 

(c) Borrower
has taken commercially reasonable steps to protect the proprietary nature of the Intellectual Property and to maintain in confidence
all trade secrets and confidential information owned, used, or held for use by Borrower in the business, including proprietary
Software. To the Knowledge of Borrower, no trade secret or other confidential information of the business has been disclosed or
authorized to be disclosed to any Person, other than pursuant to a non-disclosure agreement or other conditional obligation that
protects Borrower’s proprietary interests in and to such trade secrets or confidential Intellectual Property.

 

(d) Other
than in connection with Permitted Transfers, except for restrictions that are unenforceable under Article 9 of the UCC, (i) Borrower
has the right to freely transfer, license or assign Intellectual Property rights owned, used or held for use in the business to
any third party, including under this Agreement, and (ii) except as disclosed to Agent pursuant to Section 7.19(b), no in-bound
License (other than commercially available over-the-counter Software) prohibits or otherwise restricts Borrower from
granting a security interest in such License. Neither the consummation of the transactions contemplated by this Agreement, nor
Borrower’s performance hereunder or thereunder, will result in the diminution, license, transfer, termination or forfeiture
of Borrower’s rights in any Intellectual Property owned, used or held for use in the Borrower’s business or otherwise
impair Borrower’s ability to conduct its business as currently conducted.

 

5.9. Litigation. There
is no action, suit or proceeding pending or, to Borrower’s knowledge, currently threatened in writing against Borrower or
that Borrower intends to initiate, that questions the validity of this Agreement, or the right of Borrower to enter into any such
agreements, or to consummate the transactions contemplated hereby or thereby, or that would reasonably be expected to result, either
individually or in the aggregate, in any Material Adverse Effect. Borrower is not a party or subject to the provisions of any order,
writ, injunction, judgment or decree of any court or government agency or instrumentality which would reasonably be expected to
reasonably be expected to result in any Material Adverse Effect. To Borrower’s knowledge, no event or condition exists on
the basis of which any such claim, litigation, arbitration, mediation proceeding or investigation might be instituted or commenced.

 

5.10. Intellectual
Property Claims. No Intellectual Property owned by Borrower in connection with the business has been or is subject to any actual
or, to the knowledge of Borrower, threatened litigation, claim, invitation to license, demand, proceeding (including any proceeding
in the United States Patent and Trademark Office or any corresponding foreign office or agency) (“IP Claims”). To the
knowledge of the Borrower, no Intellectual Property licensed to Borrower by third parties and used or held for use in the business
is subject to any such IP Claims. No such Intellectual Property is subject to any outstanding decree, order, judgment, arbitral
award, settlement agreement or other stipulation that restricts Borrower’s use, transfer or licensing thereof or this Agreement
or that affects the validity, use or enforceability thereof, or obliges Borrower to grant licenses or an ownership interest in
such Intellectual Property to any third-party in the future. As of the date hereof, Borrower has not received any written notice
or claim, or, to the knowledge of Borrower, oral notice or claim, challenging in any way Borrower’s ownership or licensing
of any Intellectual Property owned, used or held for use in the business. No Intellectual Property owned by the Borrower and used
or held for use in the business infringes in any respect the Intellectual Property rights of any third party (“Third Party
IP Rights”). To the Knowledge of the Borrower, no Intellectual Property licensed to Borrower and used or held for use in
the business infringes any Third Party IP Rights.

 

    18

     

    

 

5.11. Financial
Accounts. Schedule 5.11, as may be updated by Borrower in a written notice provided to Agent after the date hereof, is a true,
correct and complete list of (a) all banks and other financial institutions at which Borrower or any Subsidiary maintains
Deposit Accounts and (b) all institutions at which Borrower or any Subsidiary maintains an account holding Investments (other
than interests in Subsidiaries) and such exhibit correctly identifies in all material respects the name and address of each bank
or other institution, the name in which the account is held, a description of the purpose of the account, and the complete account
number therefor. Borrower does not own any Equity Interest of any Person, except for Permitted Investments.

 

5.12. Filings.
Borrower is subject to the reporting requirements of the Exchange Act of, and has filed, in a timely manner, all documents and
reports that Borrower was required to file pursuant to Section I.A.3.b of the General Instructions to Form S-3 promulgated under
the Securities Act in order for Borrower to be eligible to use Form S-3 for the two years preceding the date hereof or such shorter
time period as Borrower has been subject to such reporting requirements (the foregoing materials, together with any materials filed
by Borrower under the Exchange Act, whether or not required, collectively, the “SEC Reports”). As of the time the SEC
Reports were filed with the SEC (or if subsequently amended, when amended), (i) the SEC Reports complied as to form in all material
respects with requirements of the Securities Act and Exchange Act and the rules and regulations of the SEC promulgated thereunder,
and (ii) none of the SEC Reports and the information contained therein contained any untrue statement of a material fact or omitted
to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances
under which they were made, not misleading in any material respect.

 

5.13. Brokers;
Directed Selling Efforts. None of Borrower, its Affiliates or any person acting on its or their behalf has engaged in any directed
selling efforts (within the meaning of Regulation S under the Securities Act) with respect to the Notes or the Conversion Shares.
Borrower has not paid or agreed to pay to any person any compensation for soliciting another to purchase any securities of Borrower
in connection with this Agreement. Borrower has not taken, directly or indirectly, any action designed to or that has constituted
or that might reasonably be expected to cause or result, under the Exchange Act or otherwise, in stabilization or manipulation
of the price of any security of Borrower to facilitate the sale or resale of the stocks potentially issuable upon conversion herein
in violation of the Securities Act.

 

5.14. Registration;
Trust Indenture Act. No registration under the Securities Act of the offer and sale of the common stock potentially issuable upon
conversion of the Term Loan hereunder is required for, and no qualification under the Trust Indenture Act of 1939, as amended,
and the rules and regulations of the SEC promulgated thereunder is required in connection with, the issuance of the debt security
to Lenders in the manner contemplated herein.

 

5.15. Subsidiaries.
Attached as Schedule 5.15, as may be updated by Borrower in a written notice provided after the date hereof, is a true, correct
and complete list of each Subsidiary. All of the outstanding shares of capital stock of each Subsidiary of Borrower have been duly
authorized and validly issued and are fully paid and nonassessable, and, except as otherwise set forth in the SEC Reports, all
outstanding shares of capital stock of the Subsidiaries are owned by Borrower either directly or through wholly owned subsidiaries
free and clear of any security interest, claim, lien or encumbrance (other than Permitted Liens). No Subsidiary of Borrower is
currently prohibited, directly or indirectly, from paying any dividends to Borrower, from making any other distribution on such
Subsidiary’s capital stock, from repaying to Borrower any loans or advances to such Subsidiary from Borrower or from transferring
any of such Subsidiary’s property or assets to Borrower or any other Subsidiary of Borrower, except, in each case, for restrictions
under this Agreement or as described in or contemplated in the SEC Reports.

 

    19

     

    

 

5.16. Capitalization.
The authorized, issued and outstanding capital stock of Soligenix, Inc. is as set forth in the SEC Reports; the Conversion Shares
potentially issuable herein conform in all material respects to the description thereof contained in the SEC Reports; all of the
issued and outstanding shares of capital stock have been duly authorized and validly issued, are fully paid and nonassessable and
have been issued in compliance with federal and state securities laws; none of the outstanding shares of capital stock was issued
in violation of any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase securities
of Soligenix, Inc.; there are no authorized or outstanding options, warrants, preemptive rights, rights of first refusal or other
rights to purchase, or equity or debt securities convertible into or exchangeable or exercisable for, any capital stock of Soligenix,
Inc. or any of its Subsidiaries other than those described in the SEC Reports; all grants of options to acquire shares of capital
stock were validly issued and approved by the Board of Directors of Soligenix, Inc., a committee thereof or an individual with
authority duly delegated by the Board of Directors of Soligenix, Inc. or a committee thereof; all grants of stock options and other
management equity were (a) made in compliance with all applicable laws and (b) made in compliance with the terms of the plans
under which such stock options and other management equity were issued; there is no and has been no policy or practice of Soligenix,
Inc. to coordinate the grant of stock options or other management equity with the release or other public announcement of material
information regarding the Borrower or its results of operations or prospects.

 

5.17. Reservation
of Conversion Shares. The maximum number of shares of Common Stock issuable pursuant to this Agreement have been duly authorized
and, if issued upon conversion of the Term Loan in accordance with this Agreement, will be validly issued, fully paid and nonassessable.

 

5.18. Authorized
Shares Available. On the Closing Date, immediately prior to giving effect to the transactions contemplated hereby, Soligenix, Inc.
has 75,000,000 authorized shares of Common Stock (the “Authorized Shares”); out of the available Authorized Shares,
the Board of Directors of the Borrower has duly and validly adopted resolutions reserving shares of Common Stock for potential
issuance of the Conversion Shares; the holders of outstanding shares of capital stock of the Borrower are not entitled to preemptive
or other rights to subscribe for any of the Conversion Shares.

 

5.19. Transfer
Taxes. There are no stamp or other issuance or transfer taxes or duties or other similar fees or charges required to be paid in
in connection with the execution and delivery of the Agreement.

 

5.20. Tax
Returns. Borrower and each of its Subsidiaries have filed all applicable Tax returns that are required to be filed or has timely
requested extensions thereof (except in any case in which the failure to so file would not reasonably be expected to have a Material
Adverse Effect and except as set forth or contemplated in the SEC Reports) and have paid all Taxes required to be paid by it and
any other assessment, fine or penalty levied against it, to the extent that any of the foregoing is due and payable, except for
(i) any such Tax that is currently being contested in good faith, (ii) as would not reasonably be expected to have a Material Adverse
Effect or (iii) as set forth in or contemplated in the SEC Reports.

 

5.21. Insurance.
Neither Borrower nor any of its Subsidiaries has any reason to believe that it will not be able to renew its existing insurance
coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue
its business at a cost that would not reasonably be expected to have a Material Adverse Effect except as set forth or contemplated
in the SEC Reports.

 

5.22. Regulatory
Agencies. Borrower and its Subsidiaries possess and are in compliance in all material respects with the terms of all licenses,
approvals, orders, certificates, permits and other authorizations (collectively, “Regulatory Licenses”) issued by all
applicable authorities, including, without limitation, all such Regulatory Licenses required by the U.S. Food and Drug Administration
or any component thereof and/or by any other U.S. state, local or foreign drug regulatory agency (collectively, the “Regulatory
Agencies”) necessary to conduct their respective businesses as described in the SEC Reports, and neither Borrower nor any
such Subsidiary has received any written notice of proceedings relating to the revocation or modification of, or non-compliance
with, any such Regulatory License that, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding,
would reasonably be expected to have a Material Adverse Effect, except as set forth or contemplated in the SEC Reports, and all
such Regulatory Licenses are in full force and effect.

 

5.23. Clinical
Trials. The preclinical tests and clinical trials that are described in, or the results of which are referred to in, the SEC Reports
were and, if still pending, are being conducted in all material respects in accordance with protocols filed with the appropriate
Regulatory Agencies for each such test or trial, as the case may be, and with standard medical and scientific research procedures
and all applicable statutes, directives, rules and regulations of the Regulatory Agencies, including, without limitation, the Federal
Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder; each description of such tests and trials, and
the results thereof, contained in the SEC Reports is accurate and complete in all material respects and fairly presents the data
about and derived from such tests and trials, and Borrower has no knowledge of any other studies or tests, the results of which
are inconsistent with, or otherwise call into question, the results described or referred to in the SEC Reports; neither Borrower
nor its Subsidiaries has received any notices or other correspondence from any Regulatory Agency requiring the termination, suspension
or material modification of any clinical trials that are described or referred to in the SEC Reports; and each of Borrower and
its Subsidiaries has operated and currently is in compliance in all material respects with all applicable rules and regulations
of the Regulatory Agencies.

 

    20

     

    

 

5.24. Other
Regulatory Requirements. Borrower and each of its Subsidiaries: (a) are and have been in material compliance with applicable health
care laws, including, without limitation, the Federal Food, Drug and Cosmetic Act (21 U.S.C. § 301 et seq.), the Federal Anti-kickback
Statute (42 U.S.C. § 1320a-7b(b)), the Physician Payment Sunshine Act (42 U.S.C. § 1320a-7h), the civil False Claims
Act (31 U.S.C. §§ 3729 et seq.), the administrative False Claims Law (42 U.S.C. § 1320a-7b(a)), the
Anti-Inducement Law (42 U.S.C. § 1320a-7a(a)(5)), the Health Insurance Portability and Accountability Act of 1996 (42 U.S.C.
§ 1320d et seq.), as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, the exclusion
laws, Social Security Act § 1128 (42 U.S.C. § 1320a-7), Medicare (Title XVIII of the Social Security Act), Medicaid (Title
XIX of the Social Security Act) and the regulations promulgated pursuant to such laws, and comparable state laws, and all other
local, state, federal, national, supranational and foreign laws, and regulations relating to the regulation of Borrower and its
Subsidiaries (collectively, “Health Care Laws”); (b) have not received written notice of any ongoing claim, action,
suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any Regulatory Agency or third party alleging
that any product operation or activity is in material violation of any Health Care Laws and has no knowledge that any such Regulatory
Agency or third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding; and (c) are
not a party to any corporate integrity agreement, deferred prosecution agreement, monitoring agreement, consent decree, settlement
order or similar agreements or have any reporting obligations pursuant to any such agreement, plan or correction or other remedial
measure entered into with any Governmental Authority. Neither Borrower nor its Subsidiaries or, to the knowledge of Borrower, any
of their officers, directors, employees, agents or contractors has been or is currently debarred, suspended or excluded from participation
in the Medicare and Medicaid programs or any other state or federal health care program.

 

5.25. Internal
Controls. Soligenix, Inc. and each of its Subsidiaries maintain a system of internal accounting controls sufficient to provide
reasonable assurance that (a) transactions are executed in accordance with management’s general or specific authorizations;
(b) transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted
accounting principles in the United States and to maintain asset accountability; (c) access to assets is permitted only in
accordance with management’s general or specific authorization; and (d) the recorded accountability for assets is compared
with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. Soligenix, Inc.
and its Subsidiaries’ internal controls over financial reporting are effective, and Borrower and its Subsidiaries are not
aware of any material weakness in their internal control over financial reporting.

 

5.26. Disclosure
Controls. Soligenix, Inc. and its Subsidiaries maintain “disclosure controls and procedures” (as such term is defined
in Rules 13a-15(e) under the Exchange Act); such disclosure controls and procedures are effective to provide reasonable assurance
that information required to be disclosed in Soligenix, Inc.’s Exchange Act reports is recorded, processed, summarized and
reported within the time periods specified by the SEC and that material information related to Soligenix, Inc. and its consolidated
Subsidiaries is made known to management, including Soligenix, Inc.’s Chief Executive Officer and Chief Financial Officer,
particularly during the period when Soligenix, Inc.’s periodic reports are being prepared to allow timely decisions regarding
required disclosure.

 

5.27. Environmental
Laws. Except as set forth in or contemplated in the SEC Reports, Borrower and its Subsidiaries (a) are in compliance with any and
all applicable foreign, federal, state and local laws and regulations relating to the protection of human health and safety, the
environment or hazardous or toxic substances or wastes, pollutants or contaminants (“Environmental Laws”); (b) have
received and are in compliance with all permits, licenses or other approvals required of them under applicable Environmental Laws
to conduct their respective businesses; and (c) have not received written notice of any actual or potential liability under any
Environmental Law, in each case, except where such non-compliance with Environmental Laws, failure to receive and comply with required
permits, licenses or other approvals or liability would not, individually or in the aggregate, reasonably be expected to have a
Material Adverse Effect. Except as set forth in the SEC Reports, neither Borrower nor any of its Subsidiaries has been named as
a “potentially responsible party” under the Comprehensive Environmental Response, Compensation and Liability Act of
1980, as amended.

 

    21

     

    

 

5.28. Employment
Laws. None of the following events has occurred or exists: (a) a failure to fulfill the obligations, if any, under the minimum
funding standards of Section 302 of the United States Employee Retirement Income Security Act of 1974, as amended (“ERISA”),
and the regulations and published interpretations thereunder with respect to a Plan (as defined below), determined without regard
to any waiver of such obligations or extension of any amortization period; (b) an audit or investigation by the Internal Revenue
Service, the U.S. Department of Labor, the Pension Benefit Guaranty Corporation or any other federal or state governmental agency
or any foreign regulatory agency with respect to the employment or compensation of employees by any of Borrower or any of its Subsidiaries
that could have a Material Adverse Effect, except as set forth or contemplated in the SEC Reports; (c) any breach of any contractual
obligation, or any violation of law or applicable qualification standards, with respect to the employment or compensation of employees
by Borrower or any of its Subsidiaries that could have a Material Adverse Effect, except as set forth or contemplated in the SEC
Reports. None of the following events has occurred or is reasonably likely to occur: (i) a material increase in the aggregate amount
of contributions required to be made to all Plans in the current fiscal year of Borrower and its Subsidiaries compared to the amount
of such contributions made in the most recently completed fiscal year of Borrower and its Subsidiaries; (ii) a material increase
in the “accumulated post-retirement benefit obligations” (within the meaning of FASB ASC Topic 715) of Borrower and
its Subsidiaries compared to the amount of such obligations in the most recently completed fiscal year of Borrower and its Subsidiaries;
(iii) any event or condition giving rise to a liability under Title IV of ERISA that could have a Material Adverse Effect, except
as set forth in or contemplated in the SEC Reports; or (iv) the filing of a claim by one or more employees or former employees
of Borrower or any of its Subsidiaries related to their employment that could have a Material Adverse Effect, except as set forth
or contemplated in the SEC Reports. For purposes of this paragraph, the term “Plan” means a plan (within the meaning
of Section 3(3) of ERISA) subject to Title IV of ERISA with respect to which Borrower or any of its Subsidiaries may have
any liability.

 

5.29. Money
Laundering Laws. The operations of Borrower and its Subsidiaries are and have been conducted at all times in material compliance
with applicable financial recordkeeping and reporting requirements and money laundering statutes and the rules and regulations
thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency
(collectively, the “Money Laundering Laws”), and no action, suit or proceeding by or before any court or governmental
agency, authority or body or any arbitrator involving Borrower or any of its Subsidiaries with respect to the Money Laundering
Laws is pending or, to the knowledge of Borrower, threatened in writing.

 

5.30. Sarbanes-Oxley
Act. There is and has been no failure on the part of Borrower and any of Borrower’s directors or officers, in their capacities
as such, to comply with any applicable material provision of the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated
in connection therewith, including Section 402, related to loans, and Sections 302 and 906, related to certifications.

 

5.31. Material
Contracts. An accurate, current and complete list of the Material Contracts as of the Closing Date has been furnished to Lenders
and/or is available as part of the SEC Reports. To the knowledge of Borrower, each of the Material Contracts is in full force and
effect and is a valid and binding obligation of the parties thereto in accordance with the terms and conditions thereof (except
as such enforceability may be limited by bankruptcy, insolvency, reorganization, liquidation, moratorium or other similar laws
of general application and equitable principles relating to or affecting creditors’ rights). Borrower and, to the knowledge
of Borrower, any other party to a Material Contract, is not in default with respect to any material term or condition of any Material
Contract to which it is a party. Further, Borrower has received no written notice, nor does Borrower have any knowledge, of any
pending or contemplated termination of any of the Material Contracts and no such termination is proposed or has been threatened
in writing.

 

5.32. Disclosure

 

5.33. . 
No written representation or warranty of Borrower contained in this Agreement, and no certificate furnished or to be furnished
to Lenders on the Closing Date, as of the date such representation, warranty, or other statement was made or certificate was delivered,
taken together with all such written representations, warranties and certificates, contains any untrue statement of a material
fact or, to the Borrower’s knowledge, omits to state a material fact necessary in order to make the statements contained
herein or therein not materially misleading in light of the circumstances under which they were made (it being recognized that
the projections and forecasts provided by Borrower in good faith and based upon reasonable assumptions are not viewed as facts
and that actual results during the period or periods covered by such projections and forecasts may materially differ from the
projected or forecasted results).

 

SECTION 6. INSURANCE; INDEMNIFICATION

 

6.1. Coverage.
Borrower shall cause to be carried and maintained general liability insurance, on an occurrence form, against risks customarily
insured against in Borrower’s line of business by companies of similar size in similar locations. So long as there are any
Secured Obligations (other than inchoate indemnification or reimbursement obligations or other obligations which, by their terms,
survive termination of this Agreement) outstanding, Borrower shall also cause to be carried and maintained insurance upon the Collateral,
insuring against all risks of physical loss or damage howsoever caused, in an amount not less than the full replacement cost of
the Collateral, provided that such insurance may be subject to standard exceptions and deductibles.

 

    22

     

    

 

6.2. Certificates.
Subject to Section 7.20, Borrower shall deliver to Agent certificates of insurance that evidence Borrower’s compliance with
its insurance obligations in Section 6.1 and the obligations contained in this Section 6.2. Borrower’s insurance
certificate shall state Agent is an additional insured for general liability, a loss payee for all risk property damage insurance,
subject to the insurer’s approval, and a loss payee for property insurance and additional insured for liability insurance.
Attached to the certificates of insurance will be additional insured endorsements for liability and lender’s loss payable
endorsements for all risk property damage insurance. All certificates of insurance will provide for a minimum of thirty (30) days
advance written notice to Agent of cancellation (other than cancellation for non-payment of premiums, for which ten (10) days’
advance written notice shall be sufficient). Any failure of Agent to scrutinize such insurance certificates for compliance is not
a waiver of any of Agent’s rights, all of which are reserved. Following request by Agent, Borrower shall provide Agent with
copies of each insurance policy (excluding D&O), and upon entering or materially amending any insurance policy required hereunder,
Borrower shall provide Agent with copies of such policies (excluding D&O) and shall promptly deliver to Agent updated insurance
certificates with respect to such policies.

 

6.3. Indemnity.
Borrower agrees to indemnify and hold Agent, Lenders and their respective officers, directors, employees, agents, in-house attorneys,
representatives and shareholders (each, an “Indemnified Person”) harmless from and against any and all claims, reasonable
and documented out-of-pocket costs and expenses, damages and liabilities (including such claims, costs, expenses, damages and liabilities
based on liability in tort, including strict liability in tort), including reasonable and documented out-of-pocket attorneys’
fees and disbursements and other costs of investigation or defense (including those incurred upon any appeal) (collectively, “Liabilities”),
that may be instituted or asserted against or incurred by such Indemnified Person as the result of credit having been extended,
suspended or terminated under this Agreement and the other Loan Documents or the administration of such credit, or in connection
with or arising out of the transactions contemplated hereunder and thereunder, or any actions or failures to act in connection
therewith, or arising out of the disposition or utilization of the Collateral, excluding in all cases Liabilities to the extent
resulting from any Indemnified Person’s gross negligence, willful misconduct or breach of any Loan Document. In no event
shall any party hereunder be liable on any theory of liability for any special, indirect, consequential or punitive damages (including
any loss of profits, business or anticipated savings). This Section 6.3 shall survive the repayment of indebtedness under,
and otherwise shall survive the expiration or other termination of, this Agreement. This Section 6.3 shall not apply with
respect to Taxes other than any Taxes that represent losses, claims, damages, etc. arising from any non-Tax claim.

 

SECTION 7. COVENANTS OF BORROWER

 

Borrower agrees as follows:

 

7.1. Financial
Reports. Borrower shall furnish to Lenders the financial statements and reports listed hereinafter (the “Financial Statements”):

 

(a) promptly
after the sending or filing thereof, as the case may be, copies of any proxy statements, financial statements or reports that Borrower
has made generally available to holders of its Common Stock and copies of any regular, periodic and special reports or registration
statements that Borrower files with the SEC or any Governmental Authority that may be substituted therefor, or any national securities
exchange; and

 

(b) prompt
notice if Borrower or any Subsidiary has knowledge that Borrower, or any Subsidiary or Affiliate of Borrower, is listed on the
OFAC Lists or (a) is convicted on, (b) pleads nolo contendere to, (c) is indicted on, or (d) is
arraigned and held over on charges involving money laundering or predicate crimes to money laundering.

 

(c) Borrower
shall not make any change in its fiscal years or fiscal quarters. The fiscal year of Borrower shall end on December 31. Borrower
shall provide written notice on a quarterly basis of any material changes in its accounting policies or reporting practices other
than those changes made in accordance with GAAP or IFRS, as the case may be, and accounting guidance.

 

    23

     

    

 

(d) All
Financial Statements required to be delivered pursuant to clause (a) shall be sent via e-mail to Agent provided,
that if e-mail is not available or sending such Financial Statements via e-mail is not possible, they shall
be faxed to Lenders.

 

Notwithstanding the
foregoing, any Financial Statement or document required to be delivered under this Agreement (to the extent any such documents
are included in materials otherwise filed with the SEC) shall be deemed to have been delivered on the date on which Borrower has
filed such Financial Statement or document with the SEC and such Financial Statement or document is available on the EDGAR website
on the Internet at www.sec.gov or any successor government website that is freely and readily available to Agent without charge.

 

7.2. Management
Rights. Borrower shall permit any representative that Agent authorizes, including its attorneys and accountants, to inspect the
Collateral and examine and make copies and abstracts of the books of account and records of Borrower at reasonable times and upon
reasonable prior written notice during normal business hours; provided, however, that so long as no Event of Default
has occurred and is continuing, such examinations shall be limited to no more often than once in any twelve month period. In addition,
any such representative shall have the right to meet with management and officers of Borrower to discuss such books of account
and records. In addition, Agent and Lenders shall be entitled at reasonable times and intervals to consult with and advise the
management and officers of Borrower concerning significant business issues affecting Borrower. Such consultations shall not unreasonably
interfere with Borrower’s business operations. The parties intend that the rights granted Agent and Lenders shall constitute
“management rights” within the meaning of 29 C.F.R. Section 2510.3-101(d)(3)(ii), but that any advice,
recommendations or participation by Agent or Lender with respect to any business issues shall not be deemed to give Agent or Lender,
nor be deemed an exercise by Agent or Lender of, control over Borrower’s management or policies.

 

7.3. Further
Assurances. Borrower shall from time to time execute, deliver and file, alone or with Agent, any financing statements, security
agreements, collateral assignments, notices, or other documents to perfect Agent’s Lien as a first priority lien (subject
to Permitted Liens) on the Collateral as Agent may reasonably request. Borrower shall from time to time procure any instruments
or documents as may be reasonably requested by Agent and take all further action that may be necessary or advisable, or that Agent
may reasonably request, to perfect and protect the Liens granted hereby and thereby. In addition, and for such purposes only, Borrower
hereby authorizes Agent to execute and deliver on behalf of Borrower and to file UCC financing statements (including an indication
that the financing statement covers “all assets or all personal property” of Borrower) or equivalent foreign filings,
without the signature of Borrower either in Agent’s name or in the name of Agent as agent and attorney-in-fact for
Borrower. Borrower shall in its reasonable business judgment protect and defend Borrower’s title to the Collateral and Agent’s
Lien thereon against all Persons claiming any interest adverse to Borrower or Agent other than Permitted Liens.

 

7.4. Indebtedness.
Borrower shall not create, incur, assume, guarantee or be or remain liable with respect to any Indebtedness, or permit any Subsidiary
to do so, other than Permitted Indebtedness, or prepay any Indebtedness or take any actions which impose on Borrower an obligation
to prepay any Indebtedness, at any time any amount is outstanding hereunder, except for (a) the conversion of Indebtedness
into equity securities and the payment of cash in lieu of fractional shares in connection with such conversion, (b) prepayment
by any Subsidiary of (i) inter-company Indebtedness owed by such Subsidiary to Borrower, or (ii) if such Subsidiary is
not a Borrower, intercompany Indebtedness owed by such Subsidiary to another Subsidiary that is not a Borrower (c) as otherwise
permitted hereunder or approved in writing by Agent, (d) provided that the first commercial sale of SGX301 has occurred, loans
and/or credit lines for working capital from federally chartered commercial banks, or such other lenders as may be approved by
the Lenders, in an aggregate principal amount of up to $2,500,000 or (e) Indebtedness of Borrower or its Subsidiaries made in the
OCB consistent with past business practices, in an aggregate amount of not more than $300,000 in any given calendar year.

 

    24

     

    

 

7.5. Collateral.
Borrower shall at all times keep the Collateral, the Intellectual Property and all other property and assets used in Borrower’s
business or in which Borrower now or hereafter holds any interest free and clear from any Liens (except for Permitted Liens), and
shall give Agent prompt written notice of any legal process of which Borrower has knowledge affecting the Collateral, the Intellectual
Property or Borrower’s other property and assets, in each case with a value in excess of $250,000, provided however, that
the Collateral and such other property and assets may be subject to Permitted Liens except that there shall be no Liens whatsoever
on Intellectual Property other than (i) customary restrictions on assignment, sublicense or transfer that may exist in any license
agreement where Borrower or a Subsidiary is the licensee (and not the licensor) and (ii) licenses of intellectual property that
constitute Permitted Transfers. Borrower shall not enter into or suffer to exist or become effective any agreement that prohibits
or limits the ability of Borrower to create, incur, assume or suffer to exist any Lien upon any of its property (including Intellectual
Property), whether now owned or hereafter acquired, to secure its obligations under the Loan Documents to which it is a party other
than (a) this Agreement and the other Loan Documents, and (b) in connection with any Permitted Liens or Permitted Transfers.
Borrower shall cause its Subsidiaries to protect and defend such Subsidiary’s title to its assets from and against all Persons
claiming any interest adverse to such Subsidiary (other than holders of Permitted Liens with respect to the property subject to
the Permitted Lien only), and Borrower shall cause its Subsidiaries at all times to keep such Subsidiary’s property and assets
free and clear from any Liens whatsoever (except for Permitted Liens, provided however, that there shall be no Liens whatsoever
on Intellectual Property other than (i) customary restrictions on assignment, sublicense or transfer that may exist in any license
agreement where Borrower or a Subsidiary is the licensee (and not the licensor) and (ii) licenses of intellectual property that
constitute Permitted Transfers), and shall give Agent prompt written notice of any legal process affecting such Subsidiary’s
assets.

 

7.6. Investments.
Borrower shall not directly or indirectly acquire or own, or make any Investment in or to any Person, or permit any of its Subsidiaries
to do so, other than Permitted Investments.

 

7.7. Distributions.
Borrower shall not, and shall not allow any Subsidiary to, (a) repurchase or redeem any class of stock or other Equity Interest
other than (1) pursuant to employee, director or consultant repurchase plans or other similar agreements, provided, however, in
each case cash consideration for such repurchases does not exceed in an aggregate amount not to exceed $250,000 in any fiscal year,
(2) conversions of any convertible securities into other securities pursuant to the terms of such convertible securities or otherwise
in exchange thereof and make payments in lieu of fractional shares in connection therewith, (3) repurchases where the sole consideration
for such repurchase is proceeds from a contemporaneous issuance of Equity Interests, (4) repurchases where the consideration for
such repurchase is the cancellation of Indebtedness owing to Borrower, (5) cashless settlements of options and warrants, and (6)
repurchases of Equity Interests that are deemed to occur upon the cashless exercise of options or warrants so long as no cash payment
is made by Borrower in connection therewith; or (b) declare or pay any cash dividend or make a cash distribution on any class
of stock or other Equity Interest, except that a Subsidiary may pay dividends or make distributions to Borrower, or (c) lend
money to any employees, officers or directors or guarantee the payment of any such loans granted by a third party other than Permitted
Investments.

 

7.8. Transfers.
Except for Permitted Transfers, Permitted Investments and Permitted Liens, Borrower shall not, and shall not allow any Subsidiary
to, voluntarily or involuntarily transfer, sell, lease, license, lend or in any other manner convey any equitable, beneficial or
legal interest in any material portion of its assets (including cash).

 

7.9. Mergers
or Acquisitions. Borrower shall not merge or consolidate, or permit any of its Subsidiaries to merge or consolidate, with or into
any other business organization (other than mergers or consolidations of (a) a Subsidiary which is not a Borrower into another
Subsidiary or into Borrower or (b) a Borrower into another Borrower), or acquire, or permit any of its Subsidiaries to acquire,
all or substantially all of the capital stock or property of another Person (other than any Permitted Investment). Borrower may
dissolve any Subsidiary (that is not a party to this Agreement) as long as the assets of that Subsidiary are distributed to such
Subsidiary’s shareholders and Borrower provides prompt notice to Lenders.

 

7.10. Taxes.
Borrower and its Subsidiaries shall pay when due all material taxes, fees or other charges in the nature of a tax (together with
any related interest or penalties) now or hereafter imposed or assessed against Borrower or its Subsidiaries, except for (i) any
such Tax that is currently being contested in good faith, (ii) as would not reasonably be expected to have a Material Adverse Effect
or (iii) as set forth in or contemplated in the SEC Reports. Borrower shall file on or before the due date therefor all personal
property tax returns in respect of the Collateral except as would not reasonably be expected to have a Material Adverse Effect.
For the avoidance of doubt, Borrower may contest, in good faith and by appropriate proceedings, taxes for which Borrower maintains
adequate reserves therefor in accordance with the applicable tax legislation.

 

    25

     

    

 

7.11. Corporate
Changes. Neither Borrower nor any Subsidiary shall change its corporate name, legal form or jurisdiction of formation without ten
(10) days’ prior written notice to Agent. Neither Borrower nor any Subsidiary shall suffer a Change in Control without
the approval of Agent, such approval not to be unreasonably withheld or delayed. Neither Borrower nor any Subsidiary shall relocate
its chief executive office or its principal place of business unless it has provided prior written notice to Agent. Within
thirty (30) days of the end of each fiscal quarter, Borrower shall provide written notice to Agent of any locations to which Collateral
with a value in excess of $250,000 has been relocated in the preceding fiscal quarter (other than (u) Borrower Products, including
compounds and raw materials used to manufacture biopharmaceuticals or which are used for preclinical testing or clinical trials,
in the OCB, (v) Permitted Transfers, (w) sales of Inventory in the OCB, (y) relocations of Collateral from a location
described on Schedule 5.1 to another location described on Schedule 5.1 or (z) mobile equipment in the possession of Borrower’s
or a Subsidiary’s employees or agents).

 

7.12. Joinder.
Borrower shall provide written notice to Agent within thirty (30) days of the formation of each Subsidiary formed subsequent to
the Closing Date and during such preceding fiscal quarter and shall, unless otherwise agreed by Agent, promptly cause any such
Subsidiary to execute and deliver to Agent a Joinder Agreement.

 

7.13. Notification
of Event of Default. Borrower shall notify Agent within two (2) Business Days of the occurrence of any Event of Default.

 

7.14. Use
of Proceeds. Borrower agrees that the proceeds of the Loan shall be used solely for working capital and general corporate purposes
in the OCB. The proceeds of the Loan will not be used in violation of Anti-Corruption Laws or applicable Sanctions.

 

7.15. Compliance
with Laws.

 

Borrower shall maintain,
and shall cause its Subsidiaries to maintain, compliance in all material respect with all applicable laws, rules or regulations
(including any law, rule or regulation with respect to the making or brokering of loans or financial accommodations), and shall,
or cause its Subsidiaries to, obtain and maintain all required governmental authorizations, approvals, licenses, franchises, permits
or registrations reasonably necessary in connection with the conduct of Borrower’s business, in each case, except where the
failure to do so would not reasonably be expected to result in a Material Adverse Effect.

 

Neither Borrower
nor any of its Subsidiaries shall, nor shall Borrower or any of its Subsidiaries permit, to Borrower’s knowledge, any Affiliate
to, directly or indirectly, knowingly enter into any documents, instruments, agreements or contracts with any Person listed on
the OFAC Lists. Neither Borrower nor any of its Subsidiaries shall, nor shall Borrower or any of its Subsidiaries, permit, to Borrower’s
knowledge, any Affiliate to, directly or indirectly, (i) conduct any business or engage in any transaction or dealing with
any Blocked Person, including, without limitation, the making or receiving of any contribution of funds, goods or services to or
for the benefit of any Blocked Person, (ii) deal in, or otherwise engage in any transaction relating to, any property or interests
in property blocked pursuant to Executive Order No. 13224 or any similar executive order or other Anti-Terrorism Law,
or (iii) engage in or conspire to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding,
or attempts to violate, any of the prohibitions set forth in Executive Order No. 13224 or other Anti-Terrorism Law.

 

Borrower has implemented
and maintains in effect policies and procedures designed to ensure material compliance by Borrower, its Subsidiaries and their
respective directors, officers, employees and agents with Anti-Corruption Laws and applicable Sanctions, and Borrower, its Subsidiaries
and their respective officers and employees and to the knowledge of Borrower its directors and agents, are in compliance with Anti-Corruption
Laws and applicable Sanctions in all material respects.

 

None of Borrower,
any of its Subsidiaries or any of their respective directors, officers or employees, or to the knowledge of Borrower, any agent
for Borrower or its Subsidiaries that will act in any capacity in connection with or benefit from the credit facility established
hereby, is a Sanctioned Person. No Loan, use of proceeds or other transaction contemplated by this Agreement will violate Anti-Corruption
Laws or applicable Sanctions.

 

7.16. Rule
144 Compliance.

 

(a) With
a view to making available to each Lender the benefits of Rule 144 under the Securities Act (“Rule 144”), or any similar
rule or regulation of the SEC that may at any time permit such entity to sell any portion of the Conversion Shares to the public
without registration, Soligenix, Inc. represents and warrants that: (i) it is, and has been for a period of at least ninety (90)
days immediately preceding the date hereof, subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act; (ii)
it has filed all required reports under Section 13 or 15(d) of the Exchange Act, as applicable, during the twelve (12) months preceding
the Closing Date (or for such shorter period that it was required to file such reports); (iii) it is not and never has been an
issuer defined as a “Shell Company”. For the purposes hereof, the term “Shell Company” shall mean an issuer
that meets the description set forth under Rule 144(i)(1)(i).

 

    26

     

    

 

(b) In
addition, until the earliest of (x) three (3) years from the date hereof, (y) when the Conversion Shares are no longer required
to bear a restrictive legend and (z) the effective date of the sale of all or substantially all the assets of Soligenix, Inc.,
any merger, consolidation or acquisition involving Soligenix, Inc. with, by or into another corporation, entity or person; or any
change in the ownership of more than fifty percent (50%) of the voting capital stock of Soligenix, Inc. in one or more related
transactions (such transactions described in this clause (z), a “Sale Event”), Soligenix, Inc. shall, at its sole expense,
promptly following the request of a Lender and upon the Lender providing customary supporting documentation, give its transfer
agent instructions to the effect that, upon the transfer agent’s receipt of a certificate (a “Rule 144 Certificate”)
certifying that such Lender’s holding period (as determined in accordance with the provisions of Rule 144) for any portion
of the Conversion Shares, which such Lender proposes to sell (the “Securities Being Sold”) is not less than six (6)
months and such sale otherwise complies with the requirements of Rule 144, and receipt by the transfer agent of the “Rule
144 Opinion” (as hereinafter defined) from Soligenix, Inc. or its counsel (or from such Lender and its counsel as permitted
below), the transfer agent is to effect the transfer of the Securities Being Sold and issue to such Lender or transferee(s) thereof
one or more stock certificates representing the transferred Securities Being Sold without any restrictive legend and without recording
any restrictions on the transferability of such Securities Being Sold on the transfer agent’s books and records or, at Lender’s
option, the Securities Being Sold shall be transmitted by the transfer agent to such Lender by crediting the account of Lender’s
or its designee’s balance account with The Depository Trust Company through its deposit or withdrawal at custodian system
if the transfer agent is then a participant in such system; provided that Soligenix, Inc. will not be required to do any of the
foregoing if it reasonably determines that such sale would not comply with Rule 144. In this regard, upon Lender’s request,
Soligenix, Inc. shall have an affirmative obligation at its sole expense, to cause its counsel to promptly issue to the transfer
agent a legal opinion providing that, based on the Rule 144 Certificate, the Securities Being Sold were or may be sold, as applicable,
pursuant to the provisions of Rule 144, even in the absence of an effective registration statement (the “Rule 144 Opinion”);
provided that Soligenix, Inc. will not be required to do any of the foregoing if it reasonably determines that such sale would
not comply with Rule 144. If the transfer agent requires any additional documentation in connection with any proposed transfer
by the Lender of any Securities Being Sold, such Lender shall promptly deliver or cause to be delivered to the transfer agent or
to any other Person, all such additional documentation as may be reasonably necessary to effectuate the transfer of the Securities
Being Sold and the issuance of an unlegended certificate to any transferee thereof, all at Lender’s expense.

 

7.17. Intellectual
Property. Borrower shall use commercially reasonable efforts to (i) protect, defend and maintain the validity and enforceability
of its Intellectual Property material to and used in or held for use, in its business and ascertain that such Intellectual Property
is subsisting, valid, enforceable and in full force and effect; (ii) promptly advise Agent in writing of infringements of
such Intellectual Property of which it has knowledge; and (iii) not allow any such Intellectual Property material to Borrower’s
or its Subsidiaries’ business to be abandoned, forfeited or dedicated to the public unless such abandonment, forfeiture or
dedication is in the OCB. Borrower shall provide a written report to Agent within ten (10) days of the end of each fiscal quarter
of any material in-bound or out-bound Licenses (other than over-the-counter commercially available Software) that Borrower or any
Subsidiary has entered into or become bound by in the preceding fiscal quarter.

 

7.18. Transactions
with Affiliates. Borrower shall not and shall not permit any Subsidiary to, directly or indirectly, enter into or permit to exist
any transaction of any kind with any Affiliate of Borrower or such Subsidiary on terms that are less favorable to Borrower or such
Subsidiary, as the case may be, than those that might be obtained in an arm’s length transaction from a Person who is not
an Affiliate of Borrower or such Subsidiary other than transactions, arrangements and contracts between Borrower and its Subsidiaries
or otherwise permitted pursuant to Sections 7.4, 7.5, 7.6, 7.7, 7.8, 7.9 and 7.11.

 

7.19. Financial
Covenants. For as long as the Term Loan remains outstanding, Borrower and its Subsidiaries who are a party to this Agreement or
have executed and delivered to Agent a Joinder Agreement, shall maintain a minimum Cash balance of at least $2,500,000 in the aggregate,
provided that in the event that the results of the Phase 3 DOM-INNATE (“Dusquetide treatment in Oral Mucositis – by
modulating INNATE Immunity”) study for SGX942 (dusquetide) in the treatment of oral mucositis in head and neck cancer patients
to be published by the Borrower do not meet the trial’s primary endpoints, then the minimum Cash balance will be at least
$4,500,000 in the aggregate.

 

    27

     

    

 

7.20. Post-Closing
Covenants.

 

(a) Within
five (5) day following the Closing Date, Borrower shall deliver to Agent a legal opinion of Borrower’s counsel, in substantially
the form attached hereto as Exhibit D.

 

(b) Within
45 days following the Closing Date, Borrower shall:

 

(i) deliver
to Agent legal opinions of English, Dutch and Canadian counsel regarding such matters, including capacity, applicable to the respective
Covered Foreign Subsidiary organized in such jurisdiction, as are customary for transactions of this type in the respective jurisdiction,
in each case as reasonably requested or agreed by Agent, and take or cause to be taken such actions, if any, including the execution
and delivery of any agreements, documents or instruments, necessary or advisable to enable such options to be delivered, and

 

(ii) take
or cause to be taken such actions as may be reasonably requested by Agent, including the execution and delivery of agreements,
documents or instruments, necessary or advisable to (A) create a valid and perfected Lien upon the Collateral possessed or hereafter
acquired by each Covered Foreign Subsidiary and (B) create a valid and perfected lien in the equity of each Covered Foreign Subsidiary.

 

(c) Within
30 days following any Subsidiary of Borrower becoming a party to this Agreement after the date hereof, Borrower shall take or cause
to be taken such actions, including the delivery of legal opinions and the execution and delivery of applicable agreements, documents
or instruments, as may be reasonably requested by Agent consistent with the principles described in clause (b) above.

 

(d) Within
60 days following the Closing Date (or such later date as agreed by Agent in its sole discretion), Borrower shall:

 

(i) execute
and deliver to Agent deposit account control agreement reasonably acceptable to Agent covering all of the Deposit Accounts maintained
with banks located within the United States of America and listed on Schedule 7.20 hereto (other than any Excluded Account); and

 

(ii) deliver
to Agent insurance certificates required pursuant to Section 6.2.

 

7.21. License.
Promptly following the Closing, Borrower shall enter into good faith discussions with Medison Ventures Ltd. for the purpose of
exploring the grant of licensing rights to SGX301 in Canada and Israel.

 

SECTION 8. CONVERSION 

 

8.1. Conversion
Privilege. Each Lender, at its option, shall have the right to convert at any time, all or any outstanding portion of its Term
Loans and all accrued and unpaid interest thereon into shares of Common Stock of Soligenix, Inc. at the applicable Conversion Price,
as defined below.

 

8.2. Conversion
Price. The Conversion Price for the Initial Loan and Credit Line shall be $4.10. Notwithstanding the foregoing, in the event
that on or after the Closing Date, a stock split, stock combination, reclassification, payment of stock dividend, recapitalization
or other similar transaction of such character that the shares of Common Stock shall be changed into or become exchangeable for
a larger or small number of shares is consummated (each, a “Stock Event”), the applicable Conversion Price shall be
proportionately increased or decreased as necessary to reflect the proportionate change in shares of Common Stock issued and outstanding
as a result of such Stock Event.

 

    28

     

    

 

8.3. Conversion
Mechanism. Any Lender electing to convert any portion of its then outstanding Term Loans and all accrued and unpaid interest thereon
(the “Converting Lender”), shall notify Soligenix, Inc. in writing, stating the amount the Converting Lender requests
to convert (the “Converted Amount”) and the account to which it wishes the shares of Common Stock to be delivered electronically
upon conversion (“Conversion Notice”). Soligenix, Inc. shall deliver to the Converting Lender, on or before the seventh
day following the Conversion Notice, (1) a number of shares of Common Stock equal to the Converted Amount divided by the Conversion
Price (the “Conversion Shares”) and (2) cash in lieu of fractional shares, if any. Soligenix, Inc. and Converting Lender
shall produce, execute and file any document and make any arrangement as reasonably required to perfect such conversion. The Conversion
Shares shall be fully paid, and the Conversion Shares shall be unrestricted and freely tradable securities following the earlier
of: (i) the satisfaction of the holding period for such shares required under Rule 144, or (ii) the registration of the Conversion
Shares under an effective registration statement in accordance with the Registration Rights Agreement. A Lender shall be treated
as a stockholder of record as of the Close of Business on the Business Day during which Soligenix, Inc. received the Conversion
Notice. Following conversion pursuant to this Section, the Converted Amount shall be deemed fully paid and shall no longer be deemed
a Secured Obligation hereunder.

 

In addition, Soligenix,
Inc. shall have the right to convert at any time, any outstanding portion of the Term Loans and all accrued and unpaid interest
thereon into shares of Common Stock of Soligenix, Inc. at the Conversion Price, subject to fulfilment of all of the following conditions:
(i) the shares of Common Stock issuable upon conversion are unrestricted and freely tradable securities if held by a person that
is not an affiliate (and has not been affiliate at any time during the three months preceding any such sale) of Soligenix, Inc.
pursuant to Rule 144 under the Securities Act or under an effective registration statement under the Securities Act, (ii) during
a period of 30 consecutive trading days prior to the date on which Soligenix, Inc. gives notice of the exercise of its conversion
right, the closing price of Soligenix, Inc.’s shares of common stock was higher than $4.92 on at least 10 trading
days, which trading days need not be consecutive, including on the trading day preceding the date on which Soligenix, Inc. gives
notice of the exercise of its conversion right, and (iii) the number of shares of Common Stock issuable upon conversion by Soligenix,
Inc. shall not exceed the average weekly number of traded shares on the stock market during the four weeks immediately preceding
the date on which Soligenix, Inc. gives notice of the exercise of its conversion rights. Soligenix, Inc. may only effect a conversion
once every four weeks.

 

8.4. Tax.
Soligenix, Inc. shall pay any documentary, stamp or similar issue or transfer tax due on the issue of any shares of Common Stock
upon conversion under this Section 8, unless the tax is due because the Converting Lender requests such shares to be issued in
a name other than the Converting Lender’s name.

 

8.5. Fully
Paid Shares. Soligenix, Inc. shall at all times hold, free from preemptive rights, out of its authorized, unreserved and unissued
shares or shares held in treasury, sufficient shares of Common Stock to provide for conversion as contemplated above from time
to time as such Conversion Notice is presented.

 

8.6. Effect
of Recapitalizations, Reclassifications and Changes of the Common Stock.

 

(a) In
the case of:

 

(i) any
recapitalization, reclassification or change of the Common Stock (other than changes resulting from a subdivision or combination),

 

(ii) any
consolidation, merger, combination or similar transaction involving Soligenix, Inc.,

 

(iii) any
sale, lease or other transfer to a third party of all or substantially all of the assets of Soligenix, Inc. and its Subsidiaries,
or

 

(iv) any
statutory share exchange,

 

in each case, as a
result of which the Common Stock would be converted into, or exchanged for, stock, other securities, or other property or assets
(including cash or any combination thereof) (any such event, a “Merger Event”), then, at and after the effective time
of such Merger Event, the conversion right of a Lender (and Soligenix, Inc.) shall be changed into a right to convert each $1,000
principal amount of convertible outstanding Term Loans and accrued and unpaid interest thereon into the kind and amount of shares
of stock, other securities or other property or assets (including cash or any combination thereof) that a holder of a number of
shares of Common Stock equal to the quotient of $1,000 and the applicable Conversion Price immediately prior to such Merger Event
would have owned or been entitled to receive (the “Reference Property,” with each “unit of Reference Property”
meaning the kind and amount of Reference Property that a holder of one share of Common Stock is entitled to receive) upon such
Merger Event and, prior to or at the effective time of such Merger Event, Soligenix, Inc. or the successor or purchasing Person,
as the case may be, shall execute with the Lender a supplemental agreement providing for such change in the option to convert (“Supplemental
Agreement”).

 

    29

     

    

 

(b) If
the Merger Event causes the Common Stock to be converted into, or exchanged for, the right to receive more than a single type of
consideration (determined based in part upon any form of stockholder election), then (i) the Reference Property into which the
amounts due hereunder will be convertible shall be deemed to be the weighted average of the types and amounts of consideration
actually received by the holders of Common Stock, and (ii) the unit of Reference Property for purposes of the immediately preceding
paragraph shall refer to the consideration referred to in clause (i) attributable to one share of Common Stock. If the holders
of the Common Stock receive only cash in such Merger Event, then for all conversions which occur after the effective date of such
Merger Event, (A) the consideration due upon conversion of each $1,000 principal amount of the outstanding Term Loans and accrued
and unpaid interest thereon shall be solely cash in an amount equal to quotient of $1,000 and the applicable Conversion Price multiplied
by the price paid per share of Common Stock in such Merger Event and shall be paid to the Converting Lender on or before the third
Business Day immediately following the Business Day upon which the Conversion Notice was received. Soligenix, Inc. shall notify
such Lender of any such weighted average referred to in the first sentence of this paragraph as soon as reasonably practicable
after such determination is made.

 

(c) If,
in the case of any Merger Event, the Reference Property includes shares of stock, securities or other property or assets (including
cash or any combination thereof) of a Person other than the successor or purchasing corporation, as the case may be, in such Merger
Event, then such Supplemental Agreement shall also be executed by such other Person, if such Person is an affiliate of Soligenix,
Inc.or the successor or acquiring company, and shall contain such additional provisions to protect the interests of the Converting
Lender as the board of directors of Soligenix, Inc. shall reasonably consider necessary by reason of the foregoing.

 

(d) When
Soligenix, Inc. executes a Supplemental Agreement, Soligenix, Inc. shall promptly deliver to the Lender a certificate, signed by
an Officer of Soligenix, Inc., briefly stating the reasons therefor, the kind or amount of cash, securities or property or asset
that will comprise a unit of Reference Property after any such Merger Event, any adjustment to be made with respect thereto and
that all conditions precedent have been complied with, and shall promptly mail notice thereof to all Converting Lender. Soligenix,
Inc. shall cause notice of the execution of such Supplemental Agreement to be given to the Lender within 20 days after execution
thereof. Failure to deliver such notice shall not affect the legality or validity of such Supplemental Agreement.

 

(e) Soligenix,
Inc. shall not become a party to any Merger Event unless its terms are consistent with this Section 8.6. None of the foregoing
provisions shall affect the right of the Lender to convert any portion of the Term Loan into shares of Common Stock prior to the
effective date of such Merger Event.

 

(f) The
above provisions of this Section shall similarly apply to successive Merger Events.

 

8.7. Certain
Covenants.

 

(a) Soligenix,
Inc. covenants that all shares of Common Stock issued upon conversion will be fully paid and non-assessable by Soligenix, Inc.
and free from all taxes, liens and charges with respect to the issue thereof, except with respect to any U.S. federal withholding
taxes which might apply.

 

(b) Soligenix,
Inc. covenants that, if any shares of Common Stock to be provided upon conversion require registration with or approval of any
Governmental Authority under any federal or state law before such shares of Common Stock may be validly issued, Soligenix, Inc.
shall, to the extent then permitted by the rules and interpretations of the SEC, secure such registration or approval, as the case
may be in a manner that will enable and will not delay conversion as aforesaid, unless an exemption from such registration or approval
requirements is available.

 

(c) Soligenix,
Inc. further covenants that if at any time the Common Stock shall be listed on any national securities exchange or automated quotation
system, Soligenix, Inc. will use its commercially reasonable efforts to list and keep listed, so long as the Common Stock shall
be so listed on such exchange or automated quotation system, any Common Stock issuable upon conversion hereunder.

 

    30

     

    

 

SECTION 9. EVENTS OF DEFAULT

 

The occurrence of any
one or more of the following events shall be an Event of Default:

 

9.1. Payments.
Borrower fails to pay any scheduled payment of any Secured Obligations due and owing under this Agreement or any of the other Loan
Documents within five (5) Business Days of the date when due; provided, however, that an Event of Default shall not occur on account
of a failure to pay due solely to an administrative or operational error of Agent or a Lender or Borrower’s bank if Borrower
had the funds to make the payment when due and makes the payment within three (3) Business Days following Borrower’s
knowledge of such failure to pay; or

 

9.2. Covenants.
Borrower breaches or defaults in the performance of any covenant or Secured Obligation under this Agreement, or any of the other
Loan Documents or any other agreement among Borrower, Agent and any Lender, and (a) with respect to a default under any covenant
under this Agreement (other than under Sections 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 7.13, 7.14, 7.17(b), 7.18, 7.19 and 7.20 of this
Agreement and Sections 2 and 3 of the Registration Rights Agreement) any other Loan Document or any other agreement among Borrower,
Agent and any Lender, such default continues for more than thirty (30) days after the earlier of the date on which (i) Agent
or a Lender has given notice of such default to Borrower and (ii) Borrower has actual knowledge of such default or (b) with
respect to a default under any of Sections 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 7.13, 7.14, 7.17(b), 7.18, 7.19 and 7.20 of this Agreement
and Sections 2 and 3 of the Registration Rights Agreement (except in the event that notwithstanding such breach of Sections 2 and
3 of the Registration Rights, the Lenders are eligible to sell all of their Registrable Securities by any other means without limitation
during a three-month period without registration, including through a valid exemption under the Securities Act, such as Rule 144)
the occurrence of such default; or

 

9.3. Material
Adverse Effect. A circumstance has occurred that would reasonably be expected to have a Material Adverse Effect; provided that
solely for the purposes of this Section 9.3, none of the following shall constitute by itself a Material Adverse Effect: (i)
changes in general economic or political conditions or financial credit or securities markets in general (including changes in
interest or exchange rates) or general changes in the regulation, standard terms and policies of an industry or a market, whether
worldwide or in the United States, (ii) acts of war, armed hostilities or terrorism or any escalation or worsening of any acts
of war, armed hostilities or terrorism or (iii) changes in generally accepted accounting principles; or

 

9.4. Representations.
Any representation or warranty made by Borrower in any Loan Document shall have been false or misleading in any material respect
when made or when deemed made; or

 

9.5. Insolvency.
Borrower or any Subsidiary (A) (i) shall make an assignment for the benefit of creditors; or (ii) shall be unable to
pay its debts as they become due in the ordinary course of business, or shall become insolvent (when taken as a whole on a consolidated
basis); or (iii) shall file a voluntary petition in bankruptcy; or (iv) shall file any petition, answer, or document
seeking for itself any reorganization, arrangement, composition, readjustment, liquidation, dissolution or similar relief under
any present or future statute, law or regulation pertinent to such circumstances; or (v) shall seek or consent to or acquiesce
in the appointment of any trustee, receiver, or liquidator of Borrower or such Subsidiary or of all or any material part of the
assets or property of Borrower or such Subsidiary; or (vi) shall cease operations of its business as its business has normally
been conducted, or terminate substantially all of its employees; or (vii) Borrower or a Subsidiary or its respective directors
or majority shareholders shall take any action initiating any of the foregoing actions described in clauses (i) through (vi);
or (B) either (i) forty-five (45) days shall have expired after the commencement of an involuntary action against
Borrower seeking reorganization, arrangement, composition, readjustment, liquidation, dissolution or similar relief under any present
or future statute, law or regulation, without such action being dismissed or all orders or proceedings thereunder affecting the
operations or the business of Borrower being stayed; or (ii) a stay of any such order or proceedings shall thereafter be set
aside and the action setting it aside shall not be timely appealed; or (iii) Borrower shall file any answer admitting or not
contesting the material allegations of a petition filed against Borrower in any such proceedings; or (iv) the court in which
such proceedings are pending shall enter a decree or order granting the relief sought in any such proceedings; or (v) forty-five
(45) days shall have expired after the appointment, without the consent or acquiescence of Borrower, of any trustee, receiver
or liquidator of Borrower or of all or any material part of the properties of Borrower without such appointment being vacated;
or

 

    31

     

    

 

9.6. Attachments;
Judgments. Any material portion of Borrower’s or a Subsidiary’s assets is attached or seized, or a levy is filed against
any such assets, or a judgment or judgments is/are entered against Borrower or a Subsidiary (i) for the payment of money (not covered
by independent third party insurance as to which liability has not been rejected by such insurance carrier), individually or in
the aggregate, of at least Two Hundred and Fifty Thousand Dollars ($250,000) and remains unstayed, unbonded and unsatisfied for
more than twenty (20) days past the date such judgment is required to be stayed, bonded or satisfied, or Borrower or a Subsidiary
is enjoined or in any way prevented by court order from conducting any material part of its business for more than thirty (30)
consecutive days; or

 

9.7. Other
Obligations. The occurrence of any default by Borrower or a Subsidiary under any agreement or obligation of Borrower or a Subsidiary
involving giving any third party the right to accelerate any Indebtedness in excess of Five Hundred Thousand Dollars ($500,000);
or

 

9.8. Delisting.
At any time, the Common Stock shall be delisted from the Nasdaq Stock Market and Soligenix, Inc. shall not have been able to list
the Common Stock on (i) another US national stock exchange or (ii) an inter-dealer quotation system that displays quotes, last-sale
prices, and volume information for equity securities (provided, that the Common Stock shall have been listed on the Nasdaq Stock
Market or another US national stock exchange within six (6) months of being listed on such an inter-dealer quotation system), in
each case, within sixty (60) days of such delisting; or

 

9.9. Change
in Control. The occurrence of a Change in Control of the Borrower.

 

SECTION 10. REMEDIES

 

10.1. General.
Upon and during the continuance of any one or more Events of Default, (i) Lenders shall not be required to provide any portion
of the Term Loan not yet provided or withdrawn, (ii) Agent may accelerate and demand payment of all or any part of the Secured
Obligations and declare them to be immediately due and payable (provided, that upon the occurrence of an Event of Default of the
type described in Section 9.5, all of the Secured Obligations shall automatically be accelerated and made due and payable,
in each case without any further notice or act), (iii) Agent may, at its option, sign and file in Borrower’s name any and
all collateral assignments, notices, security agreements and other documents it deems necessary or appropriate to perfect or protect
the repayment of the Secured Obligations, and in furtherance thereof, Borrower hereby grants Agent an irrevocable power of attorney
coupled with an interest, and (iv) Agent may notify any of Borrower’s account debtors to make payment directly to Agent,
compromise the amount of any such account on Borrower’s behalf and endorse Agent’s name without recourse on any such
payment for deposit directly to Agent’s account. Agent may exercise all rights and remedies with respect to the Collateral
under the Loan Documents or otherwise available to it under the UCC and other applicable law, including the right to release, hold,
sell, lease, liquidate, collect, realize upon, or otherwise dispose of all or any part of the Collateral and the right to occupy,
utilize, process and commingle the Collateral. All Agent’s rights and remedies shall be cumulative and not exclusive.

 

10.2. Collection;
Foreclosure. Upon the occurrence and during the continuance of any Event of Default, Agent may, at any time or from time to time,
apply, collect, liquidate, sell in one or more sales, lease or otherwise dispose of, any or all of the Collateral, in its then
condition or following any commercially reasonable preparation or processing, in such order as Agent may elect. Any such sale may
be made either at public or private sale at its place of business or elsewhere. Borrower agrees that any such public or private
sale may occur upon ten (10) calendar days’ prior written notice to Borrower. Agent may require Borrower to assemble
the Collateral and make it available to Agent at a place designated by Agent that is reasonably convenient to Agent and Borrower.
The proceeds of any sale, disposition or other realization upon all or any part of the Collateral shall be applied by Agent in
the following order of priorities:

 

First, to Agent and Lenders in an amount
sufficient to pay in full Agent’s and Lenders’ reasonable and documented out-of-pocket costs and professionals’
and advisors’ fees and expenses as described in Section 11.11;

 

Second, to Lenders in an amount equal to
the then unpaid amount of the Secured Obligations (including principal, interest, and the Default Rate interest), in such order
and priority as Agent may choose in its sole discretion; and

 

Finally, after the full and final payment
in Cash of all of the Secured Obligations (other than inchoate obligations and other obligations which, by their terms, survive
termination of this Agreement), to any creditor holding a junior Lien on the Collateral, or to Borrower or its representatives
or as a court of competent jurisdiction may direct.

 

    32

     

    

 

Agent shall be deemed to have acted reasonably
in the custody, preservation and disposition of any of the Collateral if it complies with the obligations of a secured party under
the UCC.

 

10.3. No
Waiver. Agent shall be under no obligation to marshal any of the Collateral for the benefit of Borrower or any other Person, and
Borrower expressly waives all rights, if any, to require Agent to marshal any Collateral.

 

10.4. Cumulative
Remedies. The rights, powers and remedies of Agent hereunder shall be in addition to all rights, powers and remedies given by statute
or rule of law and are cumulative. The exercise of any one or more of the rights, powers and remedies provided herein shall not
be construed as a waiver of or election of remedies with respect to any other rights, powers and remedies of Agent.

 

SECTION 11. MISCELLANEOUS

 

11.1. Severability.
Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Agreement shall be prohibited by or invalid under such law, such provision shall be ineffective
only to the extent and duration of such prohibition or invalidity, without invalidating the remainder of such provision or the
remaining provisions of this Agreement.

 

11.2. Notice.
Except as otherwise provided herein, any notice, demand, request, consent, approval, declaration, service of process or other communication
(including the delivery of Financial Statements) that is required, contemplated, or permitted under the Loan Documents or with
respect to the subject matter hereof shall be in writing, and shall be deemed to have been validly served, given, delivered, and
received upon the earlier of: (i) the day of transmission by electronic transmission or hand delivery or delivery by an overnight
express service or overnight mail delivery service; or (ii) the three (3) Business Days after deposit in the United States
of America mails, with proper first class postage prepaid, in each case addressed to the party to be notified as follows:

 

		(a)	If to Agent:

 

Pontifax Medison Finance GP,
L.P.,

Address: 14 Shenkar St. Herzelia,
Israel

Attention: Shlomo (Momi) Karako

Email: momi@pontifax.com

Telephone: +972-9-9725617

 

		(b)	If to Borrower:

 

Soligenix, Inc.

Address: 29 Emmons Drive, Suite
B-10

Princeton, NJ 08540

Attention: Christopher J. Schaber,
PhD

Facsimile: +1-609-452-6467

Email: cschaber@soligenix.com

Telephone: +1-609 538-8200

 

with a copy to:     Duane Morris LLP

Address: 1875
NW Corporate Boulevard, Suite 300

Boca Raton,
Florida 33431

Attention:
Driscoll R. Ugarte, P.A.

Facsimile:
+1-561-634-4260

Email: drugarte@duanemorris.com

Telephone:
561-962-2139

 

    33

     

    

 

		(c)	If to Lenders:

 

Pontifax Medison Finance (Israel)
L.P. and

Pontifax Medison Finance (Cayman) L.P.

Address: 14 Shenkar St. Herzelia,
Israel

Attention: Shlomo (Momi) Karako

Email: momi@pontifax.com

Telephone: +972-9-9725617

 

or to such other address as each
party may designate for itself by like notice.

 

11.3. Entire
Agreement; Amendments.

 

(a) This
Agreement and the other Loan Documents constitute the entire agreement and understanding of the parties hereto in respect of the
subject matter hereof and thereof, and supersede and replace in their entirety any prior proposals, term sheets, non-disclosure or
confidentiality agreements, letters, negotiations or other documents or agreements, whether written or oral, with respect to the
subject matter hereof or thereof.

 

(b) Neither
this Agreement, any other Loan Document, nor any terms hereof or thereof may be amended, supplemented or modified except in accordance
with the provisions of this Section 11.3(b). The Required Lenders and Borrower party to the relevant Loan Document may, or,
with the written consent of the Required Lenders, Agent and Borrower party to the relevant Loan Document may, from time to time,
(i) enter into written amendments, supplements or modifications hereto and to the other Loan Documents for the purpose of
adding any provisions to this Agreement or the other Loan Documents or changing in any manner the rights of Lenders or of Borrower
hereunder or thereunder or (ii) waive, on such terms and conditions as Lenders or Agent, as the case may be, may specify in
such instrument, any of the requirements of this Agreement or the other Loan Documents or any default or Event of Default and its
consequences. Any such waiver and any such amendment, supplement or modification shall apply equally to Lenders and shall be binding
upon Borrower, Lenders, Agent and all future holders of the Term Loans.

 

11.4. No
Strict Construction. The parties hereto have participated jointly in the negotiation and drafting of this Agreement. In the event
an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties
hereto and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provisions
of this Agreement.

 

11.5. No
Waiver. The powers conferred upon Agent and Lenders by this Agreement are solely to protect its rights hereunder and under the
other Loan Documents and its interest in the Collateral and shall not impose any duty upon Agent or Lenders to exercise any such
powers. No omission or delay by Agent or Lenders at any time to enforce any right or remedy reserved to it, or to require performance
of any of the terms, covenants or provisions hereof by Borrower at any time designated, shall be a waiver of any such right or
remedy to which Agent or any Lender is entitled, nor shall it in any way affect the right of Agent or Lenders to enforce such provisions
thereafter.

 

11.6. Survival.
All agreements, representations and warranties contained in this Agreement and the other Loan Documents or in any document delivered
pursuant hereto or thereto shall be for the benefit of Agent and Lenders and shall survive the execution and delivery of this Agreement.
Sections 6.3, 11.12 and 11.14 shall survive the termination of this Agreement.

 

11.7. Successors
and Assigns.

 

(a) The
provisions of this Agreement and the other Loan Documents shall inure to the benefit of and be binding on Borrower and its permitted
assigns (if any). Borrower shall not assign its obligations under this Agreement or any of the other Loan Documents without Agent’s
express prior written consent, and any such attempted assignment shall be void and of no effect. None of Agent or Lenders shall
assign its rights, interests or obligations under this Agreement or any of the other Loan Documents without Borrower’s express
prior written consent. Notwithstanding the foregoing, in all cases, any transfer to an Affiliate of a Lender or Agent and as otherwise
provided in Section 11.13 below shall be allowed.

 

    34

     

    

 

(b) Agent,
acting solely for this purpose as an agent of Borrower, shall maintain a copy of each assignment and assumption delivered to it
and a register for the recordation of the names and addresses of Lenders, and the commitments of, and principal amounts (and stated
interest) of the Term Loans owing to, Lenders pursuant to the terms hereof from time to time (the “Register”). The
entries in the Register shall be conclusive absent demonstrable error, and Borrower, Agent and Lenders shall treat each Person
whose name is recorded in the Register pursuant to the terms hereof as a Lender hereunder for all purposes of the Loan Documents.
The Register shall be available for inspection by Borrower and Lenders, at any reasonable time and from time to time upon reasonable
prior notice. Each Lender that sells a participation shall, acting solely for this purpose as a non-fiduciary agent of the Borrower,
maintain a register on which it enters the name and address of each participant and the principal amounts (and stated interest)
of each participant’s interest in the Term Loans or other obligations under the Loan Documents (the “Participant Register”);
provided that no Lender shall have any obligation to disclose all or any portion of the Participant Register (including the identity
of any participant or any information relating to a participant’s interest in any commitments, loans, letters of credit or
its other obligations under any Loan Document) to any Person except to the extent that such disclosure is necessary to establish
that such commitment, loan, letter of credit or other obligation is in registered form under Section 5f.103-1(c) of the United
States Treasury Regulations. The entries in the Participant Register shall be conclusive absent manifest error, and such Lender
shall treat each Person whose name is recorded in the Participant Register as the owner of such participation for all purposes
of this Agreement notwithstanding any notice to the contrary. For the avoidance of doubt, the Agent (in its capacity as Agent)
shall have no responsibility for maintaining a Participant Register.

 

11.8. Governing
Law. This Agreement and the other Loan Documents have been negotiated and delivered to Agent and Lenders in the State of New York
and shall have been accepted by Agent and Lender in the State of New York. Payment to Agent and Lenders by Borrower of the Secured
Obligations is due in the State of New York. This Agreement and the other Loan Documents shall be governed by, and construed and
enforced in accordance with, the laws of the State of New York, excluding conflict of laws principles that would cause the application
of laws of any other jurisdiction; provided that Section 5-1401 of the New York General Obligations Law shall apply.

 

11.9. Consent
to Jurisdiction and Venue. All judicial proceedings (to the extent that the reference requirement of Section 11.10 is not applicable)
arising in or under or related to this Agreement or any of the other Loan Documents (except as expressly provided otherwise in
any other Loan Document) shall be brought in any competent state or federal court located in New York City, New York (the “Competent
Court”). By execution and delivery of this Agreement, each party hereto generally and unconditionally: (a) submits and consents
to exclusive jurisdiction in such courts except that Agent may bring suit or take legal action in any other jurisdiction to realize
on the Collateral or any other security for the Obligations or as provided in any other Loan Document; (b) waives any objection
as to lack of jurisdiction or improper venue or forum non conveniens; and (c) irrevocably agrees to be bound by any judgment rendered
thereby in connection with this Agreement or the other Loan Documents. Service of process on any party hereto in any action arising
out of or relating to this Agreement shall be effective if given in accordance with the requirements for notice set forth in Section
11.2 and shall be deemed effective and received as set forth in Section 11.2.

 

11.10. Mutual
Waiver of Jury Trial.

 

Because disputes arising
in connection with complex financial transactions are most quickly and economically resolved by an experienced and expert Person
and the parties wish applicable state and federal laws to apply (rather than arbitration rules), the parties desire that their
disputes be resolved by a judge applying such applicable laws. EACH OF BORROWER, AGENT AND LENDERS SPECIFICALLY WAIVES ANY RIGHT
IT MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM, CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY CLAIM OR ANY OTHER CLAIM (COLLECTIVELY,
“CLAIMS”) ASSERTED BY BORROWER AGAINST AGENT, LENDERS OR THEIR RESPECTIVE ASSIGNEE OR BY AGENT, LENDERS OR THEIR RESPECTIVE
ASSIGNEE AGAINST BORROWER. This waiver extends to all such Claims, including Claims that involve Persons other than Agent, Borrower
and Lenders, Claims that arise out of or are in any way connected to the relationship among Borrower, Agent and Lenders, and any
Claims for damages, breach of contract, tort, specific performance, or any equitable or legal relief of any kind, arising out of
this Agreement, any other Loan Document.

 

    35

     

    

 

11.11. Professional
Fees. Subject to the expense cap set forth herein, Borrower promises to pay Agent’s and Lender’s reasonable and documented
out-of-pocket costs and expenses necessary to finalize the Loan Documents, including but not limited to reasonable and documented
out-of-pocket attorney’s fees, UCC searches, filing costs, and other miscellaneous expenses. In addition, Borrower promises
to pay any and all reasonable documented and out-of-pocket attorneys’ and other professionals’ fees and expenses incurred
by Agent and Lenders after the Closing Date in connection with or related to: (a) the Loan; (b) the administration, collection,
or enforcement of the Loan; (c) the amendment or modification of the Loan Documents; (d) any waiver, consent, release,
or termination under the Loan Documents; (e) the protection, preservation, audit, field exam, sale, lease, liquidation, or
disposition of Collateral or the exercise of remedies with respect to the Collateral; (f) any third party legal, litigation,
administrative, arbitration, or out of court proceeding in connection with or related to Borrower or the Collateral, and any appeal
or review thereof; and (g) any bankruptcy, restructuring, reorganization, assignment for the benefit of creditors, workout,
foreclosure, or other action related to Borrower, the Collateral, the Loan Documents, including representing Agent or Lenders in
any adversary proceeding or contested matter commenced or continued by or on behalf of Borrower’s estate, and any appeal
or review thereof.

 

11.12. Confidentiality.
Agent and Lenders acknowledge that Collateral and information provided to Agent and Lenders by Borrower are confidential and proprietary
information of Borrower (the “Confidential Information”). Accordingly, Agent and Lenders agree that any Confidential
Information it may obtain in the course of acquiring, administering, or perfecting Agent’s security interest in the Collateral
shall not be disclosed to any other Person or entity in any manner whatsoever, in whole or in part, without the prior written consent
of Borrower, except that Agent and Lenders may disclose any such information: (a) to its own directors, officers, employees,
accountants, counsel and other professional advisors and to its Affiliates if Agent or Lenders in their sole discretion determines
that any such party should have access to such information in connection with such party’s responsibilities in connection
with the Loan or this Agreement and, provided that such recipient of such Confidential Information either (i) agrees to be
bound by the confidentiality provisions of this paragraph or (ii) is otherwise subject to confidentiality restrictions that
reasonably protect against the disclosure of Confidential Information; (b) if such information is generally available to the
public without any disclosure by Agent or Lenders or breach of this Section 11.12; (c) if required or appropriate in
any report, statement or testimony submitted to any Governmental Authority having or claiming to have jurisdiction over Agent or
a Lender; (d) if required or appropriate in response to any summons or subpoena or in connection with any litigation, to the
extent permitted or deemed advisable by Agent’s or Lender’s counsel; (e) to comply with any legal requirement
or law applicable to Agent or Lenders; (f) to the extent reasonably necessary in connection with the exercise of any right
or remedy under any Loan Document, including Agent’s sale, lease, or other disposition of Collateral after default and during
the continuation of an Event of Default; (g) to any participant or assignee of Agent or Lenders or any prospective participant
or assignee; provided, that such participant or assignee or prospective participant or assignee agrees in writing to be bound by
this Section prior to disclosure; or (h) otherwise with the prior consent of Borrower; provided, that any disclosure made
in violation of this Agreement shall not affect the obligations of Borrower or any of its Affiliates or any guarantor under this
Agreement or the other Loan Documents. In handling any Confidential Information, each of Agent and Lenders shall exercise the same
degree of care that it exercises for its own proprietary information. Agent’s and Lenders’ obligations under this Section 11.12
shall supersede all of their respective obligations under any non-disclosure agreement.

 

11.13. Assignment
of Rights. Borrower acknowledges and understands that Agent or Lenders may, subject to Section 11.7, sell and assign all or
part of its interest hereunder and under the Loan Documents to any Person or entity (an “Assignee”); provided that
no such assignment shall be made without the prior written consent of Borrower, which shall not be unreasonably withheld conditioned
or delayed; provided, however, Borrower’s consent (a) may be withheld for any reason if such Assignee (i) is a competitor
of Borrower or (ii) is not engaged in the business of lending funds to borrowers in the biopharmaceutical industry and with similar
financial resources as Lender, but (b) shall not be required if such assignment occurs following an Event of Default that is continuing
or in connection with a sale or disposition of Agent or Lenders or all or a portion of a Lender’s loan portfolio, or any
merger, acquisition or corporate reorganization affecting Lender. After such assignment the term “Agent” or “Lender”
as used in the Loan Documents shall mean and include such Assignee, and such Assignee shall be vested with all rights, powers and
remedies of Agent and Lenders hereunder with respect to the interest so assigned; but with respect to any such interest not so
transferred, Agent and Lenders shall retain all rights, powers and remedies hereby given. No such assignment by Agent or Lender
shall relieve Borrower of any of its obligations hereunder. Each Lender agrees that in the event of any transfer by it of the Term
Note (if any), it will endorse thereon a notation as to the portion of the principal of the Term Note(s), which shall have been
paid at the time of such transfer and as to the date to which interest shall have been last paid thereon.

 

    36

     

    

 

11.14. Revival
of Secured Obligations. This Agreement and the Loan Documents shall remain in full force and effect and continue to be effective
if any petition is filed by or against Borrower for liquidation or reorganization, if Borrower becomes insolvent or makes an assignment
for the benefit of creditors, if a receiver or trustee is appointed for all or any significant part of Borrower’s assets,
or if any payment or transfer of Collateral is recovered from Agent or a Lender. The Loan Documents and the Secured Obligations
and Collateral security shall continue to be effective, or shall be revived or reinstated, as the case may be, if at any time payment
and performance of the Secured Obligations or any transfer of Collateral to Agent, or any part thereof is rescinded, avoided or
avoidable, reduced in amount, or must otherwise be restored or returned by, or is recovered from, Agent, a Lender or by any obligee
of the Secured Obligations, whether as a “voidable preference,” “fraudulent conveyance,” or otherwise,
all as though such payment, performance, or transfer of Collateral had not been made. In the event that any payment, or any part
thereof, is rescinded, reduced, avoided, avoidable, restored, returned, or recovered, the Loan Documents and the Secured Obligations
shall be deemed, without any further action or documentation, to have been revived and reinstated except to the extent of the full
final payment to Agent or Lenders.

 

11.15. Counterparts.
This Agreement and any amendments, waivers, consents or supplements hereto may be executed in any number of counterparts, and by
different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which
counterparts shall constitute but one and the same instrument.

 

11.16. No
Third Party Beneficiaries. No provisions of the Loan Documents are intended, nor will be interpreted, to provide or create any
third-party beneficiary rights or any other rights of any kind in any Person other than Agent, Lenders and Borrower unless specifically
provided otherwise herein, and, except as otherwise so provided, all provisions of the Loan Documents will be personal and solely
among Agent, Lenders and Borrower.

 

11.17. Agency.
Each Lender hereby irrevocably appoints Pontifax Medison Finance GP L.P. to act on its behalf as Agent hereunder and under the
other Loan Documents and authorizes Agent to take such actions on its behalf and to exercise such powers as are delegated to Agent
by the terms hereof or thereof, together with such actions and powers as are reasonably incidental thereto.

 

11.18. Publicity.
None of the parties hereto nor any of its respective member businesses and Affiliates shall, without the other parties’ prior
written consent (which shall not be unreasonably withheld or delayed), publicize or use (a) the other party’s name (including
a brief description of the relationship among the parties hereto), logo or hyperlink to such other parties’ web site, separately
or together, in written and oral presentations, advertising, promotional and marketing materials, client lists, public relations
materials or on its web site (together, the “ Publicity Materials”); (b) the names of officers of such other parties
in the Publicity Materials; and (c) such other parties’ name, trademarks, servicemarks in any news or press release
concerning such party; provided however, notwithstanding anything to the contrary herein, no such consent shall be required (i) to
the extent necessary to comply with the requests of any regulators, legal requirements or laws applicable to such party, including
pursuant to any listing agreement with any national securities exchange (so long as such party provides prior notice to the other
party hereto to the extent reasonably practicable) and (ii) to comply with Section 11.12.

 

(SIGNATURES TO FOLLOW)

 

    37

     

    

 

IN WITNESS WHEREOF, Borrower, Agent and
Lenders have duly executed and delivered this Loan and Security Agreement as of the day and year first above written.

 

	AGENT:	 
	 	 
	Pontifax Medison Finance GP L.P	 
	 	 
	By:	/s/ Shlomo Karako	 
	Name:  	Shlomo Karako	 
	Title:	Partner	 

 

	LENDERS:	 	 
	 	 	 
	Pontifax Medison Finance (Israel) L.P.	 	Pontifax Medison Finance (Cayman) L.P.
	 	 	 
	By:	/s/ Shlomo Karako	 	By:	/s/ Shlomo Karako
	Name:  	Shlomo Karako	 	Name:  	Shlomo Karako
	Title:	Partner	 	Title:	Partner

 

[Signature Page to Loan and Security Agreement]

 

     

     

    

 

	BORROWER:	 	 
	 	 	 
	Soligenix, Inc.	 	Enteron Pharmaceuticals, Inc.
	 	 	 
	By: 	/s/ Christopher J. Schaber	 	By: 	/s/ Christopher J. Schaber
	Name: 	Christopher J. Schaber, PhD	 	Name: 	Christopher J. Schaber, PhD
	Title:	 President and Chief Executive Officer	 	Title: 	President and Chief Executive Officer
	 	 	 
	Soligenix BioPharma Canada Incorporated	 	Soligenix UK Limited
	 	 	 
	By: 	/s/ Christopher J. Schaber	 	By: 	/s/ Christopher J. Schaber
	Name:   	Christopher J. Schaber, PhD	 	Name:   	Christopher J. Schaber, PhD
	Title:	 President and Chief Executive Officer	 	Title: 	President and Chief Executive Officer
	 	 	 
	Soligenix NE B.V.	 	 
	 	 	 
	By: 	/s/ Christopher J. Schaber	 	 
	Name: 	Christopher J. Schaber, PhD	 	 
	Title: 	President and Chief Executive Officer	 	 

 

[Signature Page to Loan and Security Agreement]

 

     

     

    

 

Schedules and Exhibits

 

SCHEDULES

 

	I	Subsidiaries party to the Loan and Security Agreement
	 	 
	A	Commitments
	 	 
	1A	Existing Indebtedness
	 	 
	1B	Existing Investments
	 	 
	1C	Existing Liens
	 	 
	5.1	Borrower Information; Locations
	 	 
	5.3	Consents
	 	 
	5.5	Actions Before Governmental Authorities
	 	 
	5.8(a)	Intellectual Property
	 	 
	5.11	Accounts
	 	 
	5.15	Subsidiaries
	 	 
	7.20	Deposit Accounts

 

EXHIBITS

 

	A	Form of Term Note
	 	 
	B	Form of Joinder Agreement
	 	 
	C	Compliance Certificate
	 	 
	D	Form of Legal OpinionExhibit 10.2

 

THIRD AMENDMENT

TO

EMPLOYMENT AGREEMENT

 

This
Third Amendment to Employment Agreement (the “Amendment”) is made and entered into as of December 10, 2020 by
and between Soligenix, Inc., a Delaware corporation having a place of business at 29 Emmons Drive, Suite B-10, Princeton, NJ 08540
(the “Corporation”), and Christopher J. Schaber, Ph.D. (the “Employee”).

 

RECITALS

 

WHEREAS, the
Corporation and the Employee are parties to that certain Employment Agreement dated December 27, 2007, as amended by that certain
First Amendment to Employment Agreement dated July 12, 2011 and that certain Second Amendment to Employment Agreement dated January
2, 2020 (as amended, the “Employment Agreement”), pursuant to which the Corporation employs the Employee as
President and Chief Executive Officer; and

 

WHEREAS, the
Corporation and the Employee desire to further amend the Employment Agreement in accordance with the terms thereof and upon the
terms set forth herein.

 

NOW,
THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and adequacy of which
is hereby acknowledged, the Corporation and the Employee hereby agree as follows:

 

		I.	AMENDMENT OF EMPLOYMENT AGREEMENT

 

1. Section
7(c) of the Employment Agreement is hereby amended and restated in its entirety as follows:

 

(c)
Upon termination by the Corporation without Just Cause or pursuant to subparagraphs (i), (ii) or (iv) of paragraph 7(a) of the
Employment Agreement, then (i) the term of the Employment Agreement as set forth in Section 2 thereof shall be deemed
to have been terminated as of such date, and (ii) the Corporation shall pay the Employee: (a) salary for the Serveance Period
(as defined below), (b) a pro rata bonus calculated by the average of Employee’s prior two year’s annual bonuses,
if any, and based on the number of months that Employee was employed during the year in which Employee’s employment was terminated,
and (c) any vacation accrued but not taken, payable upon the normal payroll periods of the Corporation with such payments
to begin on the first payroll period following Employee’s termination of employment. For purposes hereof, Severance Period
shall mean (i) 12 months in the case of termination by the Corporation without Just Cause or pursuant to subparagraphs (i) or (ii)
of paragraph 7(a) of the Employment Agreement; and (ii) 18 months in the case of a termination by the Corporation pursuant to subparagraph
(iv) of paragraph 7(a) of the Employment Agreement. Notwithstanding anything herein to the contrary, each payment made during the
Severance Period shall be deemed to be a separate payment within the meaning of Section 409(a) of the Code and the regulations
thereunder. Health benefits and life insurance will also be maintained for Employee (or his dependents in the event of termination
pursuant to subparagraph (i)) by the Corporation during the Severance Period. No unvested options shall vest beyond the termination
date, except where previously noted in Section 3(b) of the Employment Agreement or at the discretion of the administrators
of the Corporation’s equity compensation plans.

 

     

     

    

 

		II.	OTHER PROVISIONS INCORPORATED AND UNCHANGED

 

All
other provisions of the Employment Agreement are incorporated herein and shall remain in full force and effect, including, but
not limited to, capitalized terms that are not otherwise defined herein.

 

		III.	EFFECT OF AMENDMENT

 

The amendments to the Employment Agreement
made hereby shall be effective as of the date hereof.

 

		IV.	ENTIRE AGREEMENT MODIFICATION

 

The Employment Agreement,
as amended hereby, contains the entire agreement of the parties relating to the subject matter hereof, and the parties hereto have
made no agreements, representations or warranties relating to the subject matter hereof which are not set forth herein. No modification
hereof shall be valid unless made in writing and signed by the parties hereto.

 

		V.	GOVERNING LAW

 

This Amendment shall
be governed by, and construed and interpreted in accordance with, the laws of the State of New Jersey without regard to principles
of conflict of laws.

 

		VI.	COUNTERPARTS

 

This
Amendment may be executed in counterparts, each of which shall, when executed and delivered, constitute an original of this Amendment,
but all of which shall together constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic
mail (including pdf or any other electronic signature, e.g., www.docusign.com) or other transmission method and any counterpart
so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

 

    2

     

    

 

IN WITNESS WHEREOF,
the parties hereto have executed this Amendment as of the day and year above written.

 

	 	SOLIGENIX, INC.
	 	 
	 	By:	 /s/ Jonathan L. Guarino
	 	 	Jonathan L. Guarino, CPA
	 	 	Chief Financial Officer, Senior Vice President, and Corporate Secretary
	 	 
	 	EMPLOYEE:
	 	 
	 	By:	/s/ Christopher J. Schaber
	 	 	Christopher J. Schaber, PhD

 

 

3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00318-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00318-of-00352.parquet"}]]